🏷

Classifications

Harrison's Chapter

🔗

Mappings

MONDO

MONDO:0007739 Huntington disease

Orphanet lists MONDO:0007739 as an exact cross-reference for the ORPHA:399 Huntington disease record.

📘

Definitions

1

Orphanet Huntington disease definition

Orphanet defines Huntington disease as a rare central nervous system neurodegenerative disorder characterized by choreatic movements, psychiatric and behavioral disturbances, and dementia.

CASE_DEFINITION

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"Huntington disease (HD) is a rare neurodegenerative disorder of the central nervous system characterized by unwanted choreatic movements, behavioral and psychiatric disturbances and dementia."

Orphanet's definition supports the entry's high-level disease framing and cardinal clinical domains.

👪

Inheritance

1

Autosomal Dominant HP:0000006

HD follows autosomal dominant inheritance with complete penetrance at 40+ CAG repeats. Reduced penetrance occurs with 36-39 repeats. Anticipation is observed, particularly with paternal transmission due to meiotic instability of the CAG repeat.

Autosomal dominant inheritance Penetrance: COMPLETE

Show evidence (2 references)

PMID:41233526 SUPPORT Human Clinical

"Huntington disease is a fatal, inherited, neurodegenerative disease caused by a CAG repeat expansion in the huntingtin gene (HTT), resulting in a toxic polyglutamine tract in the huntingtin protein."

Confirms HD is an inherited disorder caused by CAG repeat expansion in HTT.

ORPHA:399 SUPPORT Other

"Autosomal dominant"

Orphanet's inheritance section directly states autosomal dominant inheritance for Huntington disease.

◆

Subtypes

3

Adult-onset Huntington Disease

Classical form with onset typically between ages 30-50, CAG repeat length 36-55, characterized by chorea, cognitive decline, and psychiatric symptoms.

Juvenile Huntington Disease (Westphal variant)

Onset before age 20, associated with longer CAG repeat expansions (usually >60), characterized by rigidity, bradykinesia, seizures, and more rapid progression rather than the chorea typical of adult-onset disease.

Late-Onset Huntington Disease

Onset over 60 years of age, accounting for roughly 4.4-11.5% of individuals with HD, and often with a slower, milder course than the typical fourth-decade onset.

Show evidence (2 references)

PMID:28671137 SUPPORT Other

"BACKGROUND: Although the typical age of onset for Huntington's disease (HD) is in the fourth decade, between 4.4-11.5% of individuals with HD have a late onset (over 60 years of age)."

Defines late-onset HD as onset over 60 years of age, occurring in 4.4-11.5% of individuals with HD, supporting the corrected subtype description.

PMID:17390259 REFUTE Other

"Huntington's disease may present at any age, but most typically manifests between the ages of 35 and 45 years as a slowly progressive neurodegenerative movement disorder with cognitive and behavioral impairment."

Refutes any characterization of late onset as beginning after age 50; HD most typically manifests between ages 35 and 45, so the late-onset subtype is best defined by onset over 60 rather than over 50.

◈

Mechanistic Hypotheses

4

Toxic Gain-of-Function (Polyglutamine Aggregation)

canonical_toxic_gain_of_function CANONICAL

The expanded polyglutamine tract in mutant huntingtin confers a toxic gain-of-function through protein misfolding, oligomerization, and aggregation into inclusion bodies. This is the widely accepted primary disease mechanism, with polyQ expansion beyond the pathogenic threshold (~36 repeats) driving neurodegeneration predominantly in the striatum.

Retained as CANONICAL. The 2026 openscientist hypothesis-search report (kb/hypotheses/Huntingtons_Disease/canonical_toxic_gain_of_function) reviewed 81 papers and found the gain-of-function model robustly validated, but identified three critical refinements: (1) **somatic CAG repeat instability** driven by MMR genes (MSH3, MSH2, PMS1, MLH1, FAN1) is an upstream amplifier that expands repeats far beyond the inherited length in vulnerable striatal MSNs — inherited repeat length is necessary but not sufficient for toxicity; (2) gain-of-function operates alongside **loss of normal HTT function** (aggregates sequester wild-type HTT) rather than independently; (3) RNA-level toxicity from expanded CAG repeats is an additional pathogenic layer independent of protein aggregation. The first-generation HTT-lowering trials' disappointing results also signal that simple mHTT removal is insufficient and reinforce the multi-layered model.

Show evidence (6 references)

PMID:22180703 SUPPORT Other

"It is caused by expansion of a polyglutamine tract within the N-terminal domain of the Huntingtin protein. The mutation confers a toxic gain-of-function phenotype, resulting in neurodegeneration that is most severe in the striatum."

Explicitly names the toxic gain-of-function phenotype as the consequence of polyQ expansion and links it to striatal neurodegeneration.

PMID:25336039 SUPPORT Other

"The mutational expansion of polyglutamine beyond a critical length produces a toxic gain of function in huntingtin and results in neuronal death. In the course of the disease, expanded huntingtin is proteolyzed, becomes abnormally folded, and accumulates in oligomers, fibrils, and microscopic inclusions."

Directly states the toxic gain-of-function framing and details the aggregation cascade from proteolysis through misfolding to inclusion body formation.

PMID:41233526 PARTIAL Other

"These findings point to somatic CAG repeat expansions"

Major review reframes HD pathogenesis: somatic CAG repeat expansion driven by DNA repair (MMR) gene activity is now recognized as a rate-limiting upstream process that determines disease onset and progression — qualifying the simple gain-of-function model with a necessary upstream-amplifier step.

+ 3 more references

Transcriptional Dysregulation

canonical_transcriptional_dysregulation CANONICAL

Mutant huntingtin disrupts transcriptional regulation by sequestering key transcription factors and co-activators (Sp1, CBP, REST/NRSF), leading to widespread downregulation of neuronal survival genes including BDNF. This is a canonical downstream mechanistic layer in HD, linking mutant huntingtin protein interactions to loss of neuronal maintenance programs.

Pathograph links

Transcriptional Dysregulation -> Mitochondrial Dysfunction INDIRECT KNOWN INTERMEDIATES Reduced transcription of PGC-1alpha-dependent mitochondrial and antioxidant programs drives downstream bioenergetic failure. Intermediates: reduced PGC-1alpha activity; impaired mitochondrial biogenesis and antioxidant defense

Show evidence (8 references)

PMID:11839795 SUPPORT Model Organism

"In HD transgenic mice (R6/2) that express N-terminal-mutant huntingtin, Sp1 binds to the soluble form of mutant huntingtin but not to aggregated huntingtin."

In vivo evidence from HD transgenic mice showing that Sp1 binds soluble mutant huntingtin, supporting the sequestration mechanism.

PMID:11839795 SUPPORT In Vitro

"Mutant huntingtin inhibits the binding of nuclear Sp1 to the promoter of nerve growth factor receptor and suppresses its transcriptional activity in cultured cells."

Cell culture experiments demonstrating that mutant huntingtin suppresses Sp1-regulated transcription.

PMID:11264541 SUPPORT In Vitro

"We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain."

HD cell culture models showing CBP depletion from its normal nuclear location and sequestration into polyglutamine aggregates.

+ 5 more references

Mitochondrial Dysfunction and Bioenergetic Failure

canonical_mitochondrial_bioenergetic_failure CANONICAL

Mutant huntingtin impairs mitochondrial function through reduced oxidative phosphorylation complex activity, disrupted calcium homeostasis, and transcriptional repression of PGC-1alpha. This is a canonical convergent mechanism in HD that links transcriptional dysregulation and mutant huntingtin stress to bioenergetic failure, oxidative damage, and neuronal death, particularly in energy-demanding striatal medium spiny neurons.

Retained as CANONICAL but reframed as a **downstream convergent mediator** rather than an independent initiating event. The 2026 openscientist hypothesis-search report (kb/hypotheses/Huntingtons_Disease/canonical_mitochondrial_bioenergetic_failure) reviewed 76 papers and identified three refinements: (1) the transcriptional-repression-of-PGC-1α pathway (PMID:17018277) is the strongest mechanistic link, validated by genetic and rescue experiments; (2) the "direct mHTT-mitochondria interaction" model is challenged by isolated-mitochondria studies, shifting emphasis toward indirect transcription-mediated mechanisms; (3) GWAS overwhelmingly implicate DNA-repair/somatic-expansion genes — not mitochondrial genes — as rate-limiting modifiers, positioning mitochondrial dysfunction as a downstream amplifier rather than an upstream driver. Failed clinical trials of mitochondrial-targeting agents (CoQ10, creatine) are consistent with this reframing. Bioenergetic failure critically synergizes with NMDAR-mediated excitotoxicity through ATP loss and Mg²⁺-block removal, creating a feedforward loop in energy-demanding striatal MSNs.

Pathograph links

Transcriptional Dysregulation -> Mitochondrial Dysfunction INDIRECT KNOWN INTERMEDIATES Reduced transcription of PGC-1alpha-dependent mitochondrial and antioxidant programs drives downstream bioenergetic failure. Intermediates: reduced PGC-1alpha activity; impaired mitochondrial biogenesis and antioxidant defense

Show evidence (3 references)

PMID:17018277 SUPPORT Model Organism

"mutant huntingtin causes disruption of mitochondrial function by inhibiting expression of PGC-1alpha"

Identifies PGC-1α transcriptional repression as the strongest mechanistic link from mHTT to mitochondrial dysfunction. PGC-1α KO crossbred with HD KI exacerbates striatal neurodegeneration; PGC-1α restoration via lentivirus is neuroprotective in HD mice — direct causal validation of the canonical pathway.

PMID:19622387 SUPPORT Other

"Nonetheless, it is becoming increasingly clear that alterations in mitochondrial function play key roles in the pathogenic processes in HD. The net result of these events is compromised energy metabolism and increased oxidative damage, which eventually contribute to neuronal dysfunction and death."

Frames mitochondrial dysfunction as a key pathogenic mechanism linking compromised energy metabolism and oxidative damage to neuronal death.

PMID:23602910 SUPPORT Other

"There is strong evidence that mitochondrial dysfunction results in neurodegeneration and may contribute to the pathogenesis of Huntington's disease (HD). Studies over the past few years have implicated an impaired function of peroxisome proliferator-activated receptor (PPAR)-gamma..."

Links PGC-1alpha impairment to mitochondrial dysfunction in HD, connecting transcriptional dysregulation of mitochondrial biogenesis genes to bioenergetic failure.

NMDA Receptor-Mediated Excitotoxicity

alternative_excitotoxicity ALTERNATIVE

Historical but still supported superimposed model proposing that mutant huntingtin and corticostriatal circuit dysfunction enhance NMDA receptor-mediated excitotoxicity in striatal medium spiny neurons. This hypothesis is best viewed as a selective-vulnerability amplifier rather than the sole initiating lesion.

Show evidence (2 references)

PMID:17188796 SUPPORT Other

"Many lines of evidence support a role for neuronal damage arising as a result of excessive activation of glutamate receptors by excitatory amino acids in the pathogenesis of Huntington disease. The N-methyl-d-aspartate subclass of ionotropic glutamate receptors (NMDARs) is more selective and..."

Comprehensive review establishing NMDAR-mediated excitotoxicity as a key pathogenic mechanism in HD with evidence from human tissue, animal models, and cell-based systems.

PMID:19279257 SUPPORT Model Organism

"This is the first direct in vivo evidence of NR2B-NMDAR-mediated excitotoxicity in the context of HD. Our results are consistent with previous suggestions that direct and/or indirect interactions of mutant huntingtin with NMDARs are a proximate cause of neurodegeneration in HD."

Provides the first direct in vivo genetic evidence for the excitotoxicity hypothesis by showing exacerbated striatal neurodegeneration when NR2B-NMDAR subunits are overexpressed in an HD mouse model.

?

Discussions and Knowledge Gaps

1

Is somatic HTT CAG expansion past a repeat-length threshold a causal, cell-autonomous trigger for medium spiny neuron degeneration, and can MSH3/FAN1-pathway modulation shift neurons below that threshold without unacceptable DNA-repair toxicity?

KNOWLEDGE GAP OPEN gap_hd_somatic_expansion_threshold_rescue

Attached to

pathophysiology#Somatic CAG Repeat Expansion pathophysiology#Medium Spiny Neuron Degeneration pathophysiology#Mutant Huntingtin Protein Aggregation

Human single-cell data now argue for a long silent phase of somatic repeat growth followed by a high-repeat toxicity threshold. A standardized isogenic striatal-neuron experiment would separate repeat-length threshold, mutant huntingtin proteostasis, and DNA-repair perturbation effects before treating somatic-expansion inhibition as a general disease-modifying strategy.

Proposed experiments

Isogenic hPSC striatal-neuron somatic-expansion threshold assay

isogenic stem-cell perturbation experiment

exp_hd_isogenic_spn_repeat_threshold_modulation

Generate isogenic hPSC-derived striatal projection neuron cultures with defined HTT CAG lengths; induce or monitor somatic expansion over maturation; perturb MSH3 and FAN1 pathway activity; then pair single-cell repeat sizing with neuronal identity, stress, survival, and mutant huntingtin aggregation readouts.

Model systems

Isogenic hPSC-derived striatal projection neuron model

Human pluripotent-stem-cell-derived striatal neuron system carrying controlled HTT CAG tracts so repeat-length distributions can be linked to cell-state and degeneration readouts in the same cells.

IPSC DERIVED MODEL

human NCBITaxon:9606

striatum

medium spiny neuron

Perturbations

HTT CAG tract length series

pathophysiology#HTT CAG Repeat Expansion

Isogenic allelic series spanning reduced-penetrance, typical adult-onset, and high-repeat HTT CAG lengths.

HTT hgnc:4851

MSH3 suppression

pathophysiology#Somatic CAG Repeat Expansion

Genetic or pharmacologic reduction of mismatch-repair activity predicted to slow somatic CAG expansion.

MSH3

FAN1 enhancement

pathophysiology#Somatic CAG Repeat Expansion

FAN1-pathway enhancement to test whether repeat-stabilizing activity can preserve neuronal identity without broad DNA-repair toxicity.

FAN1

Readouts

Single-cell HTT CAG repeat-length distribution

pathophysiology#Somatic CAG Repeat Expansion

Repeat length measured in the same cells used for transcriptomic state assignment.

single-cell repeat-length sequencing long-read sequencing

Direction: POSITIVE

Medium spiny neuron identity and survival

pathophysiology#Medium Spiny Neuron Degeneration

Loss of striatal neuron markers, stress-state induction, and cell-loss readouts interpreted against CAG threshold crossing.

single-cell transcriptomic profiling cell viability assay

Direction: POSITIVE

Mutant huntingtin aggregation burden

pathophysiology#Mutant Huntingtin Protein Aggregation

Aggregation or nuclear-inclusion readout paired to repeat length.

immunofluorescence assay

Direction: POSITIVE

Controls

Isogenic non-expanded HTT neurons

Matched striatal neurons carrying nonpathogenic HTT CAG length.

Sham-edited expanded HTT neurons

Expanded-CAG neurons receiving editing or delivery controls only.

Decision criterion

The threshold model is supported if neurons crossing a prespecified high somatic-repeat range lose striatal identity and viability, and if MSH3 suppression or FAN1 enhancement reduces both threshold crossing and degeneration without broad DNA-damage readouts.

Would support

pathophysiology#Somatic CAG Repeat Expansion pathophysiology#Medium Spiny Neuron Degeneration

Would refute

pathophysiology#Somatic CAG Repeat Expansion

Show evidence (3 references)

PMID:39824182 SUPPORT Human Clinical

"Somatic expansion from 40 to 150 CAGs had no apparent cell-autonomous effect"

Establishes the threshold-like causal question by separating lower somatic expansion from the larger expansions linked to neuronal collapse.

PMID:39824182 SUPPORT Human Clinical

"somatic repeat expansion beyond 150 CAGs causes SPNs to degenerate quickly and asynchronously"

Supports testing whether repeat-stabilizing perturbations can prevent the high-repeat state in a controlled human neuronal model.

+ 1 more reference

⚙

Pathophysiology

9

HTT CAG Repeat Expansion

Huntington disease is caused by expansion of a CAG trinucleotide repeat in exon 1 of the HTT gene beyond 36 repeats. The expanded repeat produces a mutant huntingtin protein with an elongated polyglutamine tract that confers a toxic gain of function. Repeat length inversely correlates with age of onset. Normal alleles have 6-26 repeats; intermediate alleles (27-35) can expand in offspring; 36-39 repeats show reduced penetrance; 40+ repeats are fully penetrant.

Downstream

Mutant Huntingtin Protein Aggregation Expanded CAG repeat produces mutant huntingtin with toxic polyglutamine tract that misfolds and aggregates.

Somatic CAG Repeat Expansion Germline CAG repeat undergoes further somatic expansion in post-mitotic striatal neurons, accelerating disease onset.

Show evidence (2 references)

PMID:41130308 SUPPORT Human Clinical

"Huntington's Disease (HD) became the first disease mapped to a single chromosome and associated with mutations in the huntingtin (HTT) gene, specifically expansions in the trinucleotide cytosine-adenine-guanine (CAG) within exon 1."

Confirms the causative CAG repeat expansion in HTT exon 1.

PMID:41233526 SUPPORT Human Clinical

"Huntington disease is a fatal, inherited, neurodegenerative disease caused by a CAG repeat expansion in the huntingtin gene (HTT), resulting in a toxic polyglutamine tract in the huntingtin protein."

Confirms the toxic polyglutamine tract from CAG expansion as the primary molecular cause.

Somatic CAG Repeat Expansion

Somatic expansion of the CAG repeat in post-mitotic striatal neurons, driven by DNA mismatch repair machinery (particularly MSH3 and FAN1), accelerates disease progression beyond what is predicted by the inherited germline repeat length. This mechanism is now recognized as a key determinant of onset timing and a major therapeutic target. GWAS have identified DNA repair gene variants as the principal genetic modifiers of HD age of onset.

DNA mismatch repair driving somatic expansion GO:0006298

Downstream

Medium Spiny Neuron Degeneration Somatic expansion in striatal neurons exacerbates local protein toxicity and accelerates neuronal death.

Show evidence (3 references)

PMID:41233526 SUPPORT Human Clinical

"genome-wide association studies have identified genetic modifiers, mostly DNA repair genes, that significantly influence disease onset and progression. These findings point to somatic CAG repeat expansions in affected tissues as a key pathological mechanism."

GWAS studies identify DNA repair gene modifiers influencing onset via somatic CAG expansion.

PMID:33579859 SUPPORT Human Clinical

"Validation of leads including the mismatch repair protein MSH3, and interstrand cross-link repair protein FAN1, suggest the mechanism is driven by somatic CAG instability, which is supported by the protective effect of CAA substitutions in the CAG tract."

Validates MSH3 and FAN1 as key mediators of somatic CAG instability.

PMID:41130308 SUPPORT Human Clinical

"Somatic expansion of the CAG repeat length, beyond the inherited length, has been associated with hastening the onset of symptoms compared to that predicted from the germline length."

Confirms somatic expansion accelerates onset beyond germline prediction.

Mutant Huntingtin Protein Aggregation

The expanded polyglutamine tract causes mutant huntingtin to misfold and form intracellular aggregates (inclusion bodies) in neurons. These aggregates disrupt proteostasis, sequester essential cellular proteins including transcription factors (CBP, Sp1, TFIID, REST/NRSF), and interfere with transcriptional regulation, axonal transport, and synaptic function. Aberrant proteolytic cleavage by caspase-6 generates toxic N-terminal fragments that accumulate in the nucleus.

Protein aggregation GO:0070841

Downstream

Medium Spiny Neuron Degeneration Mutant huntingtin aggregates and toxic fragments cause selective death of striatal medium spiny neurons.

Transcriptional Dysregulation Nuclear mutant huntingtin and N-terminal fragments sequester transcription factors (Sp1, CBP, REST/NRSF), dysregulating neuronal gene expression.

Excitotoxicity Mutant huntingtin sensitizes striatal neurons to NMDA-receptor-mediated glutamatergic excitotoxicity.

Mitochondrial Dysfunction Mutant huntingtin impairs mitochondrial bioenergetics, contributing to oxidative stress and energy failure.

Show evidence (2 references)

PMID:18992820 SUPPORT In Vitro

"Cleavage of huntingtin by caspase-6 at amino acid 586 is a crucial event in the pathogenesis of HD. Nuclear localization of huntingtin is also an important marker of HD and preventing or delaying its nuclear accumulation is protective in disease models."

Demonstrates caspase-6 cleavage generates toxic N-terminal fragments and their nuclear accumulation drives pathogenesis.

PMID:41233526 SUPPORT Human Clinical

"Although Huntington disease has long been viewed as a consequence of age-dependent toxicity from mutant huntingtin, genome-wide association studies have identified genetic modifiers, mostly DNA repair genes, that significantly influence disease onset and progression."

Confirms the established view that mutant huntingtin protein toxicity is central to HD pathogenesis.

Medium Spiny Neuron Degeneration

GABAergic medium spiny neurons (MSNs) in the caudate nucleus and putamen are selectively vulnerable in HD. Indirect pathway MSNs expressing enkephalin and D2 dopamine receptors are affected earliest, followed by direct pathway MSNs. This selective vulnerability involves excitotoxicity from corticostriatal glutamatergic inputs, mitochondrial dysfunction, impaired BDNF signaling, and naturally low levels of protective S421 phosphorylation in striatal neurons.

Medium spiny neuron CL:1001474

Neuronal apoptosis GO:0006915 Glutamate excitotoxicity GO:0007215 Impaired BDNF trophic support GO:0031547 ↓ DECREASED

Downstream

Chorea

Cognitive Decline

Memory Impairment

Bradyphrenia

Gait Disturbance

Gait Imbalance

Clumsiness

Poor Fine Motor Coordination

Abnormality of Eye Movement

Staring Gaze

Bradykinesia

Hypokinesia

Hyperreflexia

Involuntary Movements

Speech Articulation Difficulties

Oral-pharyngeal Dysphagia

Show evidence (3 references)

PMID:41233526 SUPPORT Human Clinical

"The disease leads to progressive motor, cognitive and psychiatric decline, primarily resulting from loss of medium spiny neurons in the striatum."

Directly confirms MSN loss in the striatum as the primary cause of HD clinical manifestations.

PMID:18992820 SUPPORT In Vitro

"Huntingtin is phosphorylated on serine-421 (S421) by the pro-survival signaling protein kinases Akt and SGK. Phosphorylation of huntingtin at S421 is variable in different regions of the brain with the lowest levels observed in the striatum, which is further reduced by the mutation for..."

Explains selective striatal vulnerability through naturally low levels of neuroprotective S421 phosphorylation in the striatum.

PMID:38427495 SUPPORT In Vitro

"HTT loss or mutation has impacts on neuro-epithelial and striatal neurons maturation, and on basal DNA damage and BDNF axonal transport in post-mitotic neurons"

iPSC-derived models show HTT mutation impairs striatal neuron maturation and BDNF transport, contributing to selective vulnerability.

Neuroinflammation

Reactive microglia and astrocytes contribute to HD pathogenesis through release of pro-inflammatory cytokines (IL-6, IL-8, TNF-alpha) and impaired glutamate buffering. Microglial activation occurs early, even before symptom onset, and correlates with disease progression. Peripheral immune dysregulation is also observed.

Microglia CL:0000129 Astrocyte CL:0000127

Neuroinflammatory response GO:0150076

Downstream

Medium Spiny Neuron Degeneration Neuroinflammatory activation contributes to progressive striatal neuronal injury in HD.

Abnormality of the Sense of Smell

Show evidence (2 references)

PMID:39519337 SUPPORT Human Clinical

"Activation of the immune system and glial cell-mediated neuroinflammatory responses are early pathological features and have been found in all neurodegenerative diseases (NDDs), including HD."

Dedicated HD neuroinflammation review confirming glial-mediated neuroinflammatory responses as early pathological features of HD.

PMID:39519337 SUPPORT Human Clinical

"This review highlights the significantly elevated levels of inflammatory proteins and cellular markers observed in various HD animal models and HD patient tissues, emphasizing the critical roles of microglia, astrocytes, and oligodendrocytes in mediating neuroinflammation in HD."

Establishes microglia and astrocytes as key mediators of neuroinflammation in HD with elevated inflammatory markers in patient tissues.

Excitotoxicity

Overactivation of glutamate receptors leading to neuronal damage.

medium spiny neuron CL:1001474 astrocyte CL:0000127

chemical synaptic transmission GO:0007268 excitatory postsynaptic potential GO:0060079 response to oxidative stress GO:0006979

striatum UBERON:0002435

Downstream

Medium Spiny Neuron Degeneration Glutamate-receptor overactivation produces excitotoxic injury and death of striatal medium spiny neurons.

Seizures

Show evidence (4 references)

PMID:38776957 SUPPORT Model Organism

"We have identified transcriptional upregulation of genes encoding N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors in medium spiny neurons, the cell type preferentially lost early in HD."

The study identifies upregulation of glutamate receptors in medium spiny neurons, supporting the idea of excitotoxicity due to overactivation of these receptors leading to neuronal damage.

PMID:1464368 SUPPORT Other

"Excitotoxicity refers to neuronal cell death caused by activation of excitatory amino acid receptors. A substantial body of evidence has implicated excitotoxicity as a mechanism of cell death in both acute and chronic neurologic diseases."

This reference explains the concept of excitotoxicity and supports the idea that overactivation of glutamate receptors can lead to neuronal damage.

PMID:7590394 SUPPORT Model Organism

"Our results indicated that elevated glutamate concentrations (15 mM, 1.5 mM, and 150 microM glutamate in perfusing solutions) would significantly increased both the concentrations of 2,3 and 2,5 DHBA."

The study provides direct evidence that elevated glutamate levels increase the formation of hydroxyl radicals, implying oxidative stress induced by excitotoxicity, which supports the statement.

+ 1 more reference

Mitochondrial Dysfunction

Reduced efficiency of oxidative phosphorylation complexes, loss of mitochondrial membrane potential, and impaired mitochondrial DNA stability leading to bioenergetic failure.

medium spiny neuron CL:1001474 astrocyte CL:0000127

oxidative phosphorylation GO:0006119 mitochondrion organization GO:0007005 response to oxidative stress GO:0006979

striatum UBERON:0002435 cerebral cortex UBERON:0000956

Downstream

Medium Spiny Neuron Degeneration Bioenergetic failure and oxidative damage contribute to degeneration of energy-demanding striatal medium spiny neurons.

Weight Loss

Generalized Muscle Weakness

Show evidence (2 references)

PMID:19622387 SUPPORT Other

"Nonetheless, it is becoming increasingly clear that alterations in mitochondrial function play key roles in the pathogenic processes in HD. The net result of these events is compromised energy metabolism and increased oxidative damage, which eventually contribute to neuronal dysfunction and death."

Supports the pathophysiology entry by directly linking mitochondrial dysfunction in HD to compromised energy metabolism, oxidative damage, and neuronal death.

PMID:23602910 SUPPORT Other

"There is strong evidence that mitochondrial dysfunction results in neurodegeneration and may contribute to the pathogenesis of Huntington's disease (HD). Studies over the past few years have implicated an impaired function of peroxisome proliferator-activated receptor (PPAR)-gamma..."

Supports the mitochondrial dysfunction mechanism by connecting impaired PGC-1alpha activity to defective mitochondrial biogenesis, metabolism, and antioxidant defense in HD.

D2 Receptor Medium Spiny Neuron Selective Vulnerability

D2 receptor-expressing medium spiny neurons show earlier huntingtin aggregation and greater sensitivity to CAG somatic instability compared to D1 receptor-expressing neurons.

medium spiny neuron CL:1001474

protein aggregation GO:0070841 synaptic transmission GO:0007268

striatum UBERON:0002435

Downstream

Medium Spiny Neuron Degeneration Indirect-pathway D2 medium spiny neurons show earliest aggregation and selective vulnerability, contributing to striatal neuron loss.

Dystonia

Myoclonus

Transcriptional Dysregulation

Mutant huntingtin disrupts transcriptional regulation through sequestration of transcription factors including Sp1, CBP, and REST/NRSF, leading to widespread downregulation of neuronal genes including BDNF.

Mitochondrial Dysfunction and Bioenergetic Failure Transcriptional Dysregulation

medium spiny neuron CL:1001474

regulation of transcription by RNA polymerase II GO:0006357 chromatin remodeling GO:0006338

striatum UBERON:0002435 cerebral cortex UBERON:0000956

Downstream

Mitochondrial Dysfunction Reduced transcription of PGC-1alpha-dependent mitochondrial and antioxidant programs drives downstream bioenergetic failure.

Medium Spiny Neuron Degeneration Loss of neuronal maintenance and survival gene programs (including BDNF) contributes to medium spiny neuron degeneration.

Depression

Anxiety

Agitation

Aggressive Behavior

Compulsive Behaviors

Disinhibition

Irritability

Hallucinations

Apathy

Delusion

Hostility

Abnormal Libido

Sleep Disturbances

Show evidence (8 references)

PMID:11839795 SUPPORT Model Organism

"In HD transgenic mice (R6/2) that express N-terminal-mutant huntingtin, Sp1 binds to the soluble form of mutant huntingtin but not to aggregated huntingtin."

In vivo evidence from HD transgenic mice showing that Sp1 binds soluble mutant huntingtin, supporting the sequestration mechanism.

PMID:11839795 SUPPORT In Vitro

"Mutant huntingtin inhibits the binding of nuclear Sp1 to the promoter of nerve growth factor receptor and suppresses its transcriptional activity in cultured cells."

Cell culture experiments demonstrating that mutant huntingtin suppresses Sp1-regulated transcription.

PMID:11264541 SUPPORT In Vitro

"We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain."

HD cell culture models showing CBP depletion from its normal nuclear location and sequestration into polyglutamine aggregates.

+ 5 more references

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

35

Eye 1

Abnormality of Eye Movement FREQUENT Abnormality of eye movement HP:0000496

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0000496 | Abnormality of eye movement | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies abnormality of eye movement as a frequent Huntington disease phenotype.

Musculoskeletal 1

Generalized Muscle Weakness FREQUENT Generalized muscle weakness HP:0003324

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0003324 | Generalized muscle weakness | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies generalized muscle weakness as a frequent Huntington disease phenotype.

Nervous System 22

Chorea VERY_FREQUENT Chorea HP:0002072

Show evidence (2 references)

PMID:38861215 SUPPORT Human Clinical

"HD is characterized by the presence of chorea, alongside other hyperkinesia, parkinsonism and a combination of cognitive and behavioural features."

Confirms chorea alongside other hyperkinesias as a characteristic feature of HD.

ORPHA:399 SUPPORT Other

"HP:0002072 | Chorea | Very frequent (99-80%)"

Orphanet's curated HPO annotation classifies chorea as a very frequent Huntington disease phenotype.

Cognitive Decline VERY_FREQUENT Mental deterioration HP:0001268

Show evidence (2 references)

PMID:40874597 SUPPORT Human Clinical

"Huntington's disease (HD) is an autosomal, progressive, dominant inherited neurological disorder characterized by motor dysfunction, cognitive decline, and psychiatric symptoms."

Confirms cognitive decline as one of the three cardinal features of HD.

ORPHA:399 SUPPORT Other

"HP:0001268 | Mental deterioration | Very frequent (99-80%)"

Orphanet's curated HPO annotation classifies mental deterioration as a very frequent Huntington disease phenotype.

Depression FREQUENT Depression HP:0000716

Show evidence (2 references)

PMID:38861215 SUPPORT Human Clinical

"HD is characterized by the presence of chorea, alongside other hyperkinesia, parkinsonism and a combination of cognitive and behavioural features."

Confirms behavioral features as a core component of the HD clinical triad.

ORPHA:399 SUPPORT Other

"HP:0000716 | Depression | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies depression as a frequent Huntington disease phenotype.

Anxiety FREQUENT Anxiety HP:0000739

Show evidence (2 references)

PMID:38861215 SUPPORT Human Clinical

"HD is characterized by the presence of chorea, alongside other hyperkinesia, parkinsonism and a combination of cognitive and behavioural features."

Confirms behavioral features as a core component of the HD clinical triad.

ORPHA:399 SUPPORT Other

"HP:0000739 | Anxiety | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies anxiety as a frequent Huntington disease phenotype.

Agitation FREQUENT Agitation HP:0000713

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0000713 | Agitation | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies agitation as a frequent Huntington disease phenotype.

Aggressive Behavior FREQUENT Aggressive behavior HP:0000718

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0000718 | Aggressive behavior | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies aggressive behavior as a frequent Huntington disease phenotype.

Compulsive Behaviors FREQUENT Compulsive behaviors HP:0000722

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0000722 | Compulsive behaviors | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies compulsive behaviors as a frequent Huntington disease phenotype.

Irritability FREQUENT Irritability HP:0000737

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0000737 | Irritability | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies irritability as a frequent Huntington disease phenotype.

Hallucinations FREQUENT Hallucinations HP:0000738

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0000738 | Hallucinations | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies hallucinations as a frequent Huntington disease phenotype.

Apathy FREQUENT Apathy HP:0000741

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0000741 | Apathy | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies apathy as a frequent Huntington disease phenotype.

Delusion FREQUENT Delusion HP:0000746

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0000746 | Delusion | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies delusion as a frequent Huntington disease phenotype.

Hostility FREQUENT Anger HP:0031473

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0031473 | Hostility | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies hostility as a frequent Huntington disease phenotype.

Memory Impairment FREQUENT Memory impairment HP:0002354

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0002354 | Memory impairment | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies memory impairment as a frequent Huntington disease phenotype.

Gait Disturbance FREQUENT Gait disturbance HP:0001288

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0001288 | Gait disturbance | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies gait disturbance as a frequent Huntington disease phenotype.

Gait Imbalance FREQUENT Gait imbalance HP:0002141

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0002141 | Gait imbalance | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies gait imbalance as a frequent Huntington disease phenotype.

Bradykinesia FREQUENT Bradykinesia HP:0002067

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0002067 | Bradykinesia | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies bradykinesia as a frequent Huntington disease phenotype.

Hyperreflexia VERY_FREQUENT Hyperreflexia HP:0001347

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0001347 | Hyperreflexia | Very frequent (99-80%)"

Orphanet's curated HPO annotation classifies hyperreflexia as a very frequent Huntington disease phenotype.

Dystonia FREQUENT Dystonia HP:0001332

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0001332 | Dystonia | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies dystonia as a frequent Huntington disease phenotype.

Myoclonus FREQUENT Myoclonus HP:0001336

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0001336 | Myoclonus | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies myoclonus as a frequent Huntington disease phenotype.

Involuntary Movements FREQUENT Involuntary movements HP:0004305

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0004305 | Involuntary movements | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies involuntary movements as a frequent Huntington disease phenotype.

Seizures Seizure HP:0001250

Show evidence (1 reference)

ORPHA:399 PARTIAL Other

"HP:0001250 | Seizure | Frequent (79-30%)"

Orphanet records seizures as a frequent disease-level HPO annotation. This partially supports the seizure phenotype here, while this entry retains the juvenile-HD subtype context for clinical specificity.

Sleep Disturbances Sleep disturbance HP:0002360

Show evidence (3 references)

PMID:41722529 SUPPORT Human Clinical

"Meta-analysed prevalence of objectively-measured sleep disturbances include: 35% for periodic limb movements (PLM index>15/hour), 3% for REM sleep behaviour disorder, 5% for REM sleep without atonia, and 9% for sleep-disordered breathing (AHI>5/hour); and of self-reported measures: 29% for use..."

Systematic review with meta-analysis quantifying the prevalence of multiple sleep disturbances in HD patients.

ORPHA:399 PARTIAL Other

"HP:0100785 | Insomnia | Occasional (29-5%)"

Orphanet's insomnia annotation supports one component of the broader sleep disturbance phenotype.

ORPHA:399 PARTIAL Other

"HP:0001262 | Excessive daytime somnolence | Occasional (29-5%)"

Orphanet's excessive daytime somnolence annotation supports another component of the broader sleep disturbance phenotype.

Growth 1

Weight Loss FREQUENT Weight loss HP:0001824

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0001824 | Weight loss | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies weight loss as a frequent Huntington disease phenotype.

Other 10

Disinhibition FREQUENT Disinhibition HP:0000734

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0000734 | Disinhibition | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies disinhibition as a frequent Huntington disease phenotype.

Abnormal Libido FREQUENT Abnormal libido HP:0031845

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0031845 | Abnormal libido | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies abnormal libido as a frequent Huntington disease phenotype.

Bradyphrenia FREQUENT Abnormally slow thought process HP:0031843

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0031843 | Bradyphrenia | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies bradyphrenia as a frequent Huntington disease phenotype.

Clumsiness FREQUENT Clumsiness HP:0002312

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0002312 | Clumsiness | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies clumsiness as a frequent Huntington disease phenotype.

Poor Fine Motor Coordination FREQUENT Poor fine motor coordination HP:0007010

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0007010 | Poor fine motor coordination | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies poor fine motor coordination as a frequent Huntington disease phenotype.

Staring Gaze FREQUENT Staring gaze HP:0025401

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0025401 | Staring gaze | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies staring gaze as a frequent Huntington disease phenotype.

Hypokinesia FREQUENT Hypokinesia HP:0002375

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0002375 | Hypokinesia | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies hypokinesia as a frequent Huntington disease phenotype.

Abnormality of the Sense of Smell FREQUENT Abnormality of the sense of smell HP:0004408

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0004408 | Abnormality of the sense of smell | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies abnormality of the sense of smell as a frequent Huntington disease phenotype.

Speech Articulation Difficulties FREQUENT Speech articulation difficulties HP:0009088

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0009088 | Speech articulation difficulties | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies speech articulation difficulties as a frequent Huntington disease phenotype.

Oral-pharyngeal Dysphagia OCCASIONAL Oral-pharyngeal dysphagia HP:0200136

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0200136 | Oral-pharyngeal dysphagia | Occasional (29-5%)"

Orphanet's curated HPO annotation classifies oral-pharyngeal dysphagia as an occasional Huntington disease phenotype.

🧬

Genetic Associations

15

HTT (Causative)

Gene: HTT hgnc:4851

Show evidence (2 references)

PMID:41130308 SUPPORT Human Clinical

"Huntington's Disease (HD) became the first disease mapped to a single chromosome and associated with mutations in the huntingtin (HTT) gene, specifically expansions in the trinucleotide cytosine-adenine-guanine (CAG) within exon 1."

Confirms the CAG repeat expansion in HTT exon 1 as the causative mutation.

CGGV:assertion_617c18ee-9476-4bc0-b403-20bc55150c7c-2021-11-08T193955.489Z SUPPORT Other

ClinGen classifies the HTT-Huntington disease gene-disease relationship as definitive with autosomal dominant inheritance.

MSH3 (Modifier)

Gene: MSH3 hgnc:7326

Show evidence (1 reference)

PMID:33579859 SUPPORT Human Clinical

"Validation of leads including the mismatch repair protein MSH3, and interstrand cross-link repair protein FAN1, suggest the mechanism is driven by somatic CAG instability, which is supported by the protective effect of CAA substitutions in the CAG tract."

Identifies MSH3 as a validated modifier driving somatic CAG instability.

FAN1 (Modifier)

Gene: FAN1 hgnc:29170

Show evidence (1 reference)

PMID:33579859 SUPPORT Human Clinical

"Validation of leads including the mismatch repair protein MSH3, and interstrand cross-link repair protein FAN1, suggest the mechanism is driven by somatic CAG instability, which is supported by the protective effect of CAA substitutions in the CAG tract."

Identifies FAN1 as a protective modifier against somatic CAG expansion.

SLC2A3 (Modifier)

Gene: SLC2A3 hgnc:11007

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"SLC2A3 | solute carrier family 2 member 3 | hgnc:11007 | Modifying germline mutation in"

Orphanet's gene table lists SLC2A3 as a modifying germline mutation association for Huntington disease.

MLH1 (Genetic Modifier)

PMS1 (Genetic Modifier)

PMS2 (Genetic Modifier)

LIG1 (Genetic Modifier)

PPARGC1A (Pathophysiological Role)

SLC1A2 (Pathophysiological Role)

BDNF (Pathophysiological Role)

NTRK2 (Pathophysiological Role)

DRD1 (Pathophysiological Role)

DRD2 (Pathophysiological Role)

SQSTM1 (Pathophysiological Role)

💊

Medical Actions

13

Tetrabenazine

Action: Tetrabenazine for chorea Ontology label: Pharmacotherapy NCIT:C15986

Agent: tetrabenazine CHEBI:9467

Vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treatment of chorea in HD. Reduces dopamine signaling in the basal ganglia. Most effective of the three VMAT2 inhibitors for chorea control but associated with higher rates of sedation and carries a boxed warning for depression.

Mechanism Target:

MODULATES D2 Receptor Medium Spiny Neuron Selective Vulnerability — Tetrabenazine inhibits VMAT2, depleting presynaptic dopamine and reducing striatal dopaminergic drive to compensate for the loss of D2-receptor-bearing indirect-pathway medium spiny neurons that underlies HD chorea.

Show evidence (1 reference)

PMID:41069601 SUPPORT Human Clinical

"This study suggests that three VMAT2 inhibitors are effective in ameliorating chorea symptoms in patients with Huntington's disease. Tetrabenazine is the most effective in controlling chorea, whereas valbenazine may be the optimal choice for patients with comorbid psychiatric symptoms."

Network meta-analysis confirms tetrabenazine as the most effective VMAT2 inhibitor for chorea symptom control.

Deutetrabenazine

Action: Deutetrabenazine for chorea Ontology label: Pharmacotherapy NCIT:C15986

Deuterated form of tetrabenazine with improved pharmacokinetics and tolerability profile, approved for HD chorea. Twice-daily dosing with less CYP2D6 interaction and lower sedation risk than tetrabenazine.

Mechanism Target:

MODULATES D2 Receptor Medium Spiny Neuron Selective Vulnerability — Deutetrabenazine inhibits VMAT2, depleting presynaptic dopamine and reducing striatal dopaminergic drive to compensate for the loss of D2-receptor-bearing indirect-pathway medium spiny neurons that underlies HD chorea.

Show evidence (1 reference)

PMID:41069601 SUPPORT Human Clinical

"This study suggests that three VMAT2 inhibitors are effective in ameliorating chorea symptoms in patients with Huntington's disease. Tetrabenazine is the most effective in controlling chorea, whereas valbenazine may be the optimal choice for patients with comorbid psychiatric symptoms."

Network meta-analysis confirms deutetrabenazine efficacy for HD chorea.

Valbenazine

Action: Valbenazine for chorea Ontology label: Pharmacotherapy NCIT:C15986

Selective VMAT2 inhibitor approved in 2023 for HD chorea. Once-daily dosing with minimal CYP2D6 interaction. May be optimal for patients with comorbid psychiatric symptoms. Available in sprinkle formulation for patients with dysphagia.

Mechanism Target:

MODULATES D2 Receptor Medium Spiny Neuron Selective Vulnerability — Valbenazine selectively inhibits VMAT2, depleting presynaptic dopamine and reducing striatal dopaminergic drive to compensate for the loss of D2-receptor-bearing indirect-pathway medium spiny neurons that underlies HD chorea.

Show evidence (2 references)

PMID:41069601 SUPPORT Human Clinical

"This study suggests that three VMAT2 inhibitors are effective in ameliorating chorea symptoms in patients with Huntington's disease. Tetrabenazine is the most effective in controlling chorea, whereas valbenazine may be the optimal choice for patients with comorbid psychiatric symptoms."

Network meta-analysis identifies valbenazine as optimal for patients with comorbid psychiatric symptoms.

PMID:41069601 SUPPORT Human Clinical

"valbenazine ranked first in withdrawals due to AEs (0.735), serious adverse events (0.807), as well as in reducing both suicide (0.683) and suicidal ideation (0.748)."

In the network meta-analysis ranking (SUCRA), valbenazine was the most favorable VMAT2 inhibitor for tolerability and psychiatric-safety endpoints, including reduced suicide and suicidal ideation - relevant given the high suicide risk in Huntington disease and supporting valbenazine as the preferred agent for patients with comorbid psychiatric symptoms.

HTT-Lowering Therapies

Action: HTT-lowering gene therapy Ontology label: Pharmacotherapy NCIT:C15986

Emerging disease-modifying approaches including antisense oligonucleotides (ASOs), splice modulators, and microRNA-based gene therapy targeting mutant huntingtin protein reduction. Allele-selective approaches that spare wild-type HTT are preferred after the tominersen trial showed non-selective lowering can cause harm.

Mechanism Target:

INHIBITS HTT CAG Repeat Expansion — HTT-lowering ASOs, splice modulators, and microRNA-based therapies reduce the expression of mutant huntingtin, directly suppressing the root CAG repeat-expansion-driven toxicity at the mRNA and protein level.

INHIBITS Mutant Huntingtin Protein Aggregation — By lowering mutant HTT protein levels, these therapies reduce the substrate available for mHTT misfolding and nuclear and cytoplasmic aggregate formation.

Show evidence (2 references)

PMID:38861215 SUPPORT Human Clinical

"HD is living in an era of target-specific drug development with emphasis on the mechanisms related to mutant Huntingtin (HTT) protein. Examples include antisense oligonucleotides (ASO), splicing modifiers and microRNA molecules that aim to reduce the levels of mutant HTT protein."

Reviews the current landscape of HTT-lowering therapeutic approaches.

PMID:41090742 SUPPORT Human Clinical

"Among emerging and novel treatments for central nervous system (CNS) disorders, gene therapy (GT), particularly using adeno-associated virus (AAV)-mediated gene delivery, holds great promise."

Reviews AAV-mediated gene therapy as a promising approach for HD treatment.

Somatic Expansion Inhibition

Action: Somatic expansion inhibitor therapy Ontology label: Pharmacotherapy NCIT:C15986

Novel therapeutic paradigm targeting DNA mismatch repair machinery (particularly MSH3) to slow or halt somatic CAG repeat expansion in striatal neurons. Considered the most promising emerging strategy as it addresses the upstream DNA-level mechanism rather than downstream protein toxicity.

Mechanism Target:

INHIBITS Somatic CAG Repeat Expansion — Inhibiting MSH3 and other mismatch repair factors slows or halts the somatic CAG repeat expansion that drives progressive striatal toxicity, targeting the upstream DNA-level mechanism rather than downstream protein aggregation.

Show evidence (1 reference)

PMID:41233526 SUPPORT Human Clinical

"interventions to limit somatic repeat expansion might be effective across multiple repeat expansion diseases and, when combined with disease-specific approaches, such as huntingtin lowering in Huntington disease, might offer more effective and longer-lasting clinical benefits than either..."

Supports somatic expansion inhibition as a promising combinatorial therapeutic strategy for HD and other repeat expansion disorders.

Human Neural Stem Cell Transplantation (hNSC-01)

Action: human neural stem cell transplantation Ontology label: cellular therapy MAXO:0000016

Investigational regenerative cell therapy in which good manufacturing practice (GMP)-grade human embryonic stem cell-derived neural stem cells (hNSC-01) are stereotactically implanted into the striatum. Rather than acting by neuronal replacement alone, the grafted cells are proposed to work through neuroprotection and trophic support (including BDNF), reconstruction of striatal synaptic circuitry, and reduction of mutant huntingtin accumulation. This is the cell-therapy approach being evaluated first-in-human in the UCI Health REGEN4HD trial (NCT07451613).

Mechanism Target:

MODULATES Medium Spiny Neuron Degeneration — Intrastriatal hNSC grafts provide trophic support (notably BDNF) and synaptic/circuit reconstruction intended to protect and functionally compensate for the vulnerable striatal medium spiny neurons whose degeneration drives HD motor and cognitive decline.

INHIBITS Mutant Huntingtin Protein Aggregation — In HD mouse models, hNSC transplantation reduced aberrant accumulation of mutant huntingtin, indicating a disease-modifying effect on mHTT proteostasis beyond simple cell replacement.

Target Phenotypes: Chorea HP:0002072 Progressive cognitive decline HP:0001268

Show evidence (2 references)

PMID:29233555 SUPPORT Model Organism

"Disease-modifying activity is suggested by the reduction of aberrant accumulation of mutant HTT protein and expression of brain-derived neurotrophic factor (BDNF) in both models."

Preclinical study of the GMP-grade hNSC line that forms the basis for hNSC-01, transplanted into the striatum of R6/2 and Q140 HD mice, showed improved motor function, reduced mutant HTT accumulation, and increased BDNF, supporting a disease-modifying neurotrophic mechanism.

clinicaltrials:NCT07451613 SUPPORT Human Clinical

"to determine whether an implantation of hNSC-01 is a safe and tolerable study intervention for Huntington's disease"

The first-in-human REGEN4HD trial is evaluating intrastriatal hNSC-01 implantation for safety and tolerability in early-stage HD.

AMT-130 (AAV5-miHTT Gene Therapy)

Action: AAV5-miHTT gene therapy Ontology label: gene therapy MAXO:0001001

One-time HTT-lowering gene therapy delivering an engineered microRNA (miHTT) via an adeno-associated virus serotype 5 (rAAV5) vector by MRI-guided stereotactic infusion into the caudate and putamen. The vector-expressed miHTT drives non-allele-selective (total) lowering of huntingtin mRNA and protein in striatal neurons. In the Phase 1/2 program (NCT04120493 / NCT05243017) the high dose showed slowing of clinical progression and lowered CSF neurofilament light chain, and a BLA submission is planned.

Mechanism Target:

INHIBITS HTT CAG Repeat Expansion — The AAV5-delivered miHTT microRNA degrades huntingtin mRNA, lowering total (mutant and wild-type) huntingtin expression and thereby suppressing the downstream toxicity of the CAG-repeat-expanded transcript at its source.

INHIBITS Mutant Huntingtin Protein Aggregation — By reducing huntingtin mRNA, AMT-130 lowers mutant huntingtin protein levels, decreasing the substrate available for mHTT misfolding and aggregate formation in striatal neurons.

Target Phenotypes: Chorea HP:0002072 Progressive cognitive decline HP:0001268

Show evidence (2 references)

PMID:30984798 SUPPORT Model Organism

"AAV5-miHTT caused a dose-dependent and sustained HTT protein reduction with subsequent suppression of mutant HTT aggregate formation in the striatum and cortex."

Preclinical study of the AAV5-miHTT construct underlying AMT-130 showing dose-dependent, sustained huntingtin lowering and reduced mutant HTT aggregation after intrastriatal delivery in HD mouse models.

clinicaltrials:NCT04120493 SUPPORT Human Clinical

"This is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC)."

ClinicalTrials.gov record for the first-in-human Phase 1/2 study of the rAAV5-miHTT gene therapy AMT-130 in early manifest Huntington's disease.

Allele-Selective CRISPR/Cas9 HTT Inactivation

Action: allele-selective genome editing Ontology label: gene therapy MAXO:0001001

Genome-editing strategy that permanently inactivates the expanded (mutant) HTT allele while sparing the wild-type allele. Allele selectivity is achieved by directing Cas9 to heterozygous, allele-specific single-nucleotide polymorphisms (SNPs) that create or destroy a CRISPR PAM motif on the mutant chromosome. Preclinical proof-of-concept in HD patient cells and a transgenic HD mouse model; not yet in clinical trials.

Mechanism Target:

INHIBITS HTT CAG Repeat Expansion — Allele-selective CRISPR/Cas9 editing introduces inactivating breaks in the mutant HTT allele, permanently abolishing expression of the CAG-expanded transcript while leaving the wild-type allele intact.

Target Phenotypes: Chorea HP:0002072 Progressive cognitive decline HP:0001268

Show evidence (2 references)

PMID:28129107 SUPPORT In Vitro

"HEK293 cells, which are homozygous for the targeting SNPs (Figure 2B), were transfected with SpCas9 and sgRNA expression plasmids and genomic deletion assessed."

In vitro demonstration of SNP-dependent, allele-selective CRISPR/Cas9 excision of HTT in human cells homozygous for the targeting SNPs.

PMID:28129107 SUPPORT Model Organism

"Interestingly, mouse Htt mRNA levels were also reduced on the injected hemisphere, although to a lesser degree than the human HTT allele."

In vivo confirmation in BacHD transgenic mice (carrying the human HD allele with the targeting SNPs) that intrastriatal CRISPR/Cas9 editing lowers HTT expression on the injected hemisphere.

Human Dental Pulp Stem Cell Therapy (NestaCell)

Action: human dental pulp stem cell therapy Ontology label: cellular therapy MAXO:0000016

Investigational allogeneic cell therapy using intravenously infused human dental pulp stem cells (hDPSCs; NestaCell, formerly Cellavita HD). The rationale is neurotrophic support and modulation of neuroinflammation rather than direct neuronal replacement. A randomized, double-blind, placebo-controlled Phase II trial (NCT03252535) reported a favorable safety profile and significant improvements in motor and functional scores, supporting advancement to Phase III.

Mechanism Target:

MODULATES Medium Spiny Neuron Degeneration — Infused dental pulp stem cells are proposed to act through neurotrophic support and modulation of neuroinflammation, aiming to protect vulnerable striatal medium spiny neurons rather than replace them.

MODULATES Neuroinflammation — hDPSCs have immunomodulatory and anti-inflammatory properties hypothesized to dampen the neuroinflammatory component of HD striatal degeneration.

Target Phenotypes: Chorea HP:0002072 Progressive cognitive decline HP:0001268

Show evidence (1 reference)

PMID:40770775 SUPPORT Human Clinical

"Both doses significantly improved UHDRS-TMS compared to placebo (p = 0.005), while the 2 million cells/kg group showed significant benefits in UHDRS-TFC (p = 0.011)."

Randomized, double-blind, placebo-controlled Phase II trial of allogeneic human dental pulp stem cells (NestaCell) showing significant motor (UHDRS-TMS) and functional (UHDRS-TFC) benefit over placebo in HD.

Genetic Counseling

Action: Genetic counseling Ontology label: Genetic Counseling NCIT:C15240

Predictive genetic testing and counseling for at-risk family members. Pre-symptomatic testing follows international guidelines (HDSA/IHA/WFN) requiring pre- and post-test counseling. Only 5-20% of at-risk individuals choose predictive testing. Reproductive options include PGT-M, prenatal testing, and exclusion testing.

Supportive Care

Action: Supportive care Ontology label: Supportive Care NCIT:C15747

Multidisciplinary care including physical therapy (gait training, fall prevention), speech therapy (dysarthria and dysphagia management), occupational therapy, nutritional support (high-calorie diets, PEG tube in advanced stages), and psychiatric management (SSRIs, SNRIs for depression; antipsychotics for psychosis).

Antipsychotic Medications

Action: Pharmacotherapy NCIT:C15986

Used for psychiatric symptoms like irritability and agitation.

Show evidence (3 references)

PMID:27534434 SUPPORT Other

"In clinical practice antipsychotics represent the first choice in the management of chorea in the presence of psychiatric symptoms..."

The literature states that antipsychotics are used to manage psychiatric symptoms in Huntington's Disease.

PMID:16383221 SUPPORT Other

"According to clinical observation, HD patients with psychiatric symptoms respond to standard pharmacotherapy."

The literature supports the use of pharmacotherapy, which includes antipsychotic medications, for psychiatric symptoms in Huntington's Disease.

PMID:36496108 SUPPORT Other

"Several lines of evidence suggest a possible role of risperidone via the antagonistic effect of Dopamine D2 and 5HT-receptor in different neurological diseases like cognitive dysfunction of schizophrenia, neuroinflammation, Huntington's disease..."

Risperidone, an antipsychotic, is mentioned as having a role in treating psychiatric symptoms in Huntington's Disease.

Selective Serotonin Reuptake Inhibitors (SSRIs)

Action: Pharmacotherapy NCIT:C15986

Used to manage depression.

Show evidence (2 references)

PMID:18394562 SUPPORT Other

"Several classes of medications have been used to ameliorate the various symptoms of HD, including typical and atypical neuroleptics, dopamine depleters, antidepressants..."

The abstract mentions that antidepressants, which include SSRIs, are used to manage symptoms in Huntington's Disease.

PMID:22119091 SUPPORT Human Clinical

"Cross-sectionally, suicidal mutation carriers were more likely to use antidepressants (odds ratio=5.3)..."

The use of antidepressants, which can include SSRIs, is associated with managing depressive symptoms in Huntington's Disease.

🔬

Biochemical Markers

3

Neurofilament Light Chain (NfL)

Show evidence (2 references)

PMID:41081429 SUPPORT Human Clinical

"Evidence for neurofilament light (NfL) is sufficient to meet evidentiary guidelines as a prognostic biomarker in preHD (ie, before clinical motor diagnosis)."

Systematic review with meta-analysis establishes NfL as a validated prognostic biomarker in pre-manifest HD.

PMID:39891767 SUPPORT Human Clinical

"sNfL levels differed significantly between preHD and early HD, and HC (all p values < 0.05)"

Confirms serum NfL can distinguish pre-manifest and early HD from healthy controls.

Mutant Huntingtin Protein (mHTT)

Show evidence (1 reference)

PMID:38861215 SUPPORT Human Clinical

"The possibility of quantifying mHTT in CSF, along with the development of an integrated biological staging system in HD are important innovations applicable to clinical trial design that enhance the drug development process."

Highlights CSF mHTT quantification as a key innovation for HD clinical trial design.

Elevated Neuronal Inclusions (Positive)

Show evidence (4 references)

PMID:22200539 SUPPORT Other

"Here we will review the state of knowledge of HD, focusing especially on a hallmark pathological feature-intracellular aggregates of mutant Htt called inclusion bodies (IBs)."

The article discusses the presence of intracellular aggregates of mutant huntingtin, which are referred to as inclusion bodies, supporting the statement.

PMID:38810948 SUPPORT Human Clinical

"We confirmed the presence of mHtt aggregates within grafts of all three cases as well as tau neuropil threads in the grafts of two of the three transplanted HD patients."

The study confirms the presence of mutant huntingtin (mHtt) aggregates within neurons, supporting the statement.

PMID:19172113 SUPPORT Other

"It is likely that the aggregates containing expanded huntingtin are toxic to neurons, but it remains to be determined whether the oligomer or the inclusion is the toxic species."

The article mentions that aggregates containing expanded huntingtin are found in neurons, supporting the statement.

+ 1 more reference

🔬

Clinical Trials

3

NCT07451613 PHASE_I RECRUITING

REGEN4HD — the first-in-human Phase 1b/2a study (UCI Health) evaluating the safety and tolerability of hNSC-01, GMP-grade human embryonic stem cell-derived neural stem cells, stereotactically implanted into the striatum of adults with genetically confirmed early-stage Huntington's disease. The Phase 1b arm is a dose-escalation cohort followed by a Phase 2a expansion group, with treatment-related adverse events as the primary outcome.

Target Phenotypes: Chorea HP:0002072 Progressive cognitive decline HP:0001268

Show evidence (1 reference)

clinicaltrials:NCT07451613 SUPPORT Human Clinical

"to determine whether an implantation of hNSC-01 is a safe and tolerable study intervention for Huntington's disease"

ClinicalTrials.gov record for REGEN4HD describes the first-in-human evaluation of intrastriatal hNSC-01 neural stem cell therapy for safety and tolerability in Huntington's disease.

NCT04120493 PHASE_I ACTIVE_NOT_RECRUITING

First-in-human Phase 1/2, randomized, double-blind, sham-controlled and open-label study of striatally-administered rAAV5-miHTT total HTT-lowering gene therapy (AMT-130) in early manifest Huntington's disease. The high-dose cohort showed slowing of clinical progression and lowered CSF neurofilament light chain at 36 months.

Target Phenotypes: Chorea HP:0002072 Progressive cognitive decline HP:0001268

Show evidence (1 reference)

clinicaltrials:NCT04120493 SUPPORT Human Clinical

"This is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC)."

ClinicalTrials.gov record for the first-in-human gene therapy trial of AAV5-miHTT (AMT-130) in early manifest Huntington's disease.

NCT03252535 PHASE_II COMPLETED

Phase II, single-center, randomized (2:2:1), triple-blind, placebo-controlled dose-response study of intravenous allogeneic human dental pulp stem cells (Cellavita HD / NestaCell) in Huntington's disease. Reported a favorable safety profile with significant motor and functional improvement over placebo, supporting advancement to Phase III.

Target Phenotypes: Chorea HP:0002072 Progressive cognitive decline HP:0001268

Show evidence (1 reference)

clinicaltrials:NCT03252535 SUPPORT Human Clinical

"Cellavita HD is a stem-cell therapy for Huntington's Disease."

ClinicalTrials.gov record describing the Phase II dental pulp stem cell (Cellavita HD) study in Huntington's disease.

{ }

Source YAML

click to show

name: Huntington Disease
creation_date: "2026-04-07T12:00:00Z"
updated_date: "2026-05-21T04:04:17Z"
category: Mendelian
description: >-
  Huntington disease (HD) is an autosomal dominant neurodegenerative disorder caused by
  an expanded CAG trinucleotide repeat in the huntingtin (HTT) gene on chromosome 4p16.3.
  The expansion produces a mutant huntingtin protein with an abnormally long polyglutamine
  tract, leading to progressive neuronal dysfunction and death, particularly in the
  striatum and cortex. HD is characterized by a triad of motor dysfunction (chorea),
  cognitive decline, and psychiatric disturbances, typically manifesting in midlife
  with relentless progression over 15-20 years.
disease_term:
  preferred_term: Huntington disease
  term:
    id: MONDO:0007739
    label: Huntington disease
gene_sets:
- gene_set: MYGENESET:KEGG_HUNTINGTONS_DISEASE
  relationship: CANONICAL_PATHWAY
  note: >-
    KEGG Huntington disease pathway.
parents:
- Neurodegenerative Disorders
- Trinucleotide Repeat Disorders
synonyms:
- Huntington's Chorea
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0007739
      label: Huntington disease
    mapping_predicate: skos:exactMatch
    mapping_source: ORPHA:399
    mapping_justification: >-
      Orphanet lists MONDO:0007739 as an exact cross-reference for the
      ORPHA:399 Huntington disease record.
external_assertions:
- name: Orphanet Huntington disease structured record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:399
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=399
  description: >-
    Orphanet records Huntington disease as ORPHA:399 and provides curated
    inheritance, onset, epidemiology, gene, HPO phenotype, and external
    cross-reference rows used here as structured evidence.
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ORPHA:399  Huntington disease"
    explanation: >-
      The Orphanet structured record heading identifies ORPHA:399 as the
      Huntington disease record.
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0007739 | Exact"
    explanation: >-
      Orphanet maps ORPHA:399 exactly to the same MONDO disease identifier used
      by this entry.
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:143100 | Exact"
    explanation: >-
      Orphanet lists OMIM:143100 as an exact cross-reference for Huntington
      disease.
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICD-10:G10 | Exact"
    explanation: >-
      Orphanet lists ICD-10 G10 as an exact cross-reference for Huntington
      disease.
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICD-11:8A01.10 | Exact"
    explanation: >-
      Orphanet lists ICD-11 8A01.10 as an exact cross-reference for Huntington
      disease.
definitions:
- name: Orphanet Huntington disease definition
  definition_type: CASE_DEFINITION
  description: >-
    Orphanet defines Huntington disease as a rare central nervous system
    neurodegenerative disorder characterized by choreatic movements, psychiatric
    and behavioral disturbances, and dementia.
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Huntington disease (HD) is a rare neurodegenerative disorder of the central nervous system characterized by unwanted choreatic movements, behavioral and psychiatric disturbances and dementia.
    explanation: >-
      Orphanet's definition supports the entry's high-level disease framing and
      cardinal clinical domains.
has_subtypes:
- name: Adult-onset HD
  display_name: Adult-onset Huntington Disease
  description: >-
    Classical form with onset typically between ages 30-50, CAG repeat length
    36-55, characterized by chorea, cognitive decline, and psychiatric symptoms.
- name: Juvenile HD
  display_name: Juvenile Huntington Disease (Westphal variant)
  description: >-
    Onset before age 20, associated with longer CAG repeat expansions (usually >60),
    characterized by rigidity, bradykinesia, seizures, and more rapid progression
    rather than the chorea typical of adult-onset disease.
- name: Late-onset HD
  display_name: Late-Onset Huntington Disease
  description: >
    Onset over 60 years of age, accounting for roughly 4.4-11.5% of individuals
    with HD, and often with a slower, milder course than the typical fourth-decade
    onset.
  evidence:
  - reference: PMID:28671137
    reference_title: "What do we know about Late Onset Huntington's Disease?"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: 'BACKGROUND: Although the typical age of onset for Huntington''s disease (HD) is in the fourth decade, between 4.4-11.5% of individuals with HD have a late onset (over 60 years of age).'
    explanation: Defines late-onset HD as onset over 60 years of age, occurring in 4.4-11.5% of individuals with HD, supporting the corrected subtype description.
  - reference: PMID:17390259
    reference_title: "Huntington's Disease."
    supports: REFUTE
    evidence_source: OTHER
    snippet: Huntington's disease may present at any age, but most typically manifests between the ages of 35 and 45 years as a slowly progressive neurodegenerative movement disorder with cognitive and behavioral impairment.
    explanation: Refutes any characterization of late onset as beginning after age 50; HD most typically manifests between ages 35 and 45, so the late-onset subtype is best defined by onset over 60 rather than over 50.
inheritance:
- name: Autosomal Dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  penetrance: COMPLETE
  description: >-
    HD follows autosomal dominant inheritance with complete penetrance at 40+ CAG
    repeats. Reduced penetrance occurs with 36-39 repeats. Anticipation is observed,
    particularly with paternal transmission due to meiotic instability of the CAG repeat.
  evidence:
  - reference: PMID:41233526
    reference_title: "Huntington disease: somatic expansion, pathobiology and therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Huntington disease is a fatal, inherited, neurodegenerative disease caused
      by a CAG repeat expansion in the huntingtin gene (HTT), resulting in a toxic
      polyglutamine tract in the huntingtin protein.
    explanation: >-
      Confirms HD is an inherited disorder caused by CAG repeat expansion in HTT.
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal dominant"
    explanation: >-
      Orphanet's inheritance section directly states autosomal dominant
      inheritance for Huntington disease.
prevalence:
- population: Western populations (USA, Canada, Europe)
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_low: 8.2
  rate_high: 9.0
  percentage: 8.2-9.0 per 100,000
  evidence:
  - reference: PMID:34350853
    reference_title: "Modeling Manifest Huntington's Disease Prevalence Using Diagnosed Incidence and Survival Time."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diagnosed prevalence is estimated to be 8.2-9.0 per 100,000 in the USA,
      Canada, and the 5 included European countries and 3.5 per 100,000 in Brazil.
    explanation: >-
      Epidemiological model using diagnosed incidence and survival data from
      eight countries estimates HD prevalence in Western populations.
- population: Worldwide (Orphanet point prevalence)
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_low: 1.0
  rate_high: 9.0
  percentage: 1-9 / 100 000
  notes: >-
    Orphanet classifies worldwide Huntington disease point prevalence as 1-9
    per 100,000.
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Worldwide | Point prevalence | PMID:22692795"
    explanation: >-
      Orphanet's epidemiology table provides the worldwide point-prevalence
      class for Huntington disease.
- population: United States (Orphanet point prevalence)
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_low: 1.0
  rate_high: 9.0
  percentage: 1-9 / 100 000
  notes: >-
    Orphanet classifies United States Huntington disease point prevalence as
    1-9 per 100,000.
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | United States | Point prevalence | PMID:8018043"
    explanation: >-
      Orphanet's epidemiology table provides a United States point-prevalence
      class for Huntington disease.
progression:
- phase: Age of onset
  age_range: Childhood, adolescent, adult, or elderly
  notes: >-
    Orphanet lists Huntington disease onset categories spanning childhood
    through elderly onset.
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Childhood"
    explanation: >-
      Orphanet includes childhood among Huntington disease onset categories.
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Adolescent"
    explanation: >-
      Orphanet includes adolescent among Huntington disease onset categories.
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Adult"
    explanation: >-
      Orphanet includes adult among Huntington disease onset categories.
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Elderly"
    explanation: >-
      Orphanet includes elderly among Huntington disease onset categories.
pathophysiology:
- name: HTT CAG Repeat Expansion
  conforms_to: "polyglutamine_expansion_proteotoxicity#Translated CAG / Polyglutamine Repeat Expansion"
  description: >-
    Huntington disease is caused by expansion of a CAG trinucleotide repeat in exon 1
    of the HTT gene beyond 36 repeats. The expanded repeat produces a mutant huntingtin
    protein with an elongated polyglutamine tract that confers a toxic gain of function.
    Repeat length inversely correlates with age of onset. Normal alleles have 6-26
    repeats; intermediate alleles (27-35) can expand in offspring; 36-39 repeats show
    reduced penetrance; 40+ repeats are fully penetrant.
  evidence:
  - reference: PMID:41130308
    reference_title: "Inhibiting Cytosine-Adenine-Guanine (CAG) repeat expansions as a therapeutic strategy for Huntington's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Huntington's Disease (HD) became the first disease mapped to a single
      chromosome and associated with mutations in the huntingtin (HTT) gene,
      specifically expansions in the trinucleotide cytosine-adenine-guanine (CAG)
      within exon 1.
    explanation: >-
      Confirms the causative CAG repeat expansion in HTT exon 1.
  - reference: PMID:41233526
    reference_title: "Huntington disease: somatic expansion, pathobiology and therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Huntington disease is a fatal, inherited, neurodegenerative disease caused
      by a CAG repeat expansion in the huntingtin gene (HTT), resulting in a toxic
      polyglutamine tract in the huntingtin protein.
    explanation: >-
      Confirms the toxic polyglutamine tract from CAG expansion as the primary
      molecular cause.
  downstream:
  - target: Mutant Huntingtin Protein Aggregation
    description: >-
      Expanded CAG repeat produces mutant huntingtin with toxic polyglutamine tract
      that misfolds and aggregates.
  - target: Somatic CAG Repeat Expansion
    description: >-
      Germline CAG repeat undergoes further somatic expansion in post-mitotic
      striatal neurons, accelerating disease onset.
- name: Somatic CAG Repeat Expansion
  description: >-
    Somatic expansion of the CAG repeat in post-mitotic striatal neurons, driven by
    DNA mismatch repair machinery (particularly MSH3 and FAN1), accelerates disease
    progression beyond what is predicted by the inherited germline repeat length.
    This mechanism is now recognized as a key determinant of onset timing and a
    major therapeutic target. GWAS have identified DNA repair gene variants as the
    principal genetic modifiers of HD age of onset.
  biological_processes:
  - preferred_term: DNA mismatch repair driving somatic expansion
    term:
      id: GO:0006298
      label: mismatch repair
  evidence:
  - reference: PMID:41233526
    reference_title: "Huntington disease: somatic expansion, pathobiology and therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      genome-wide association studies have identified genetic modifiers, mostly
      DNA repair genes, that significantly influence disease onset and progression.
      These findings point to somatic CAG repeat expansions in affected tissues as
      a key pathological mechanism.
    explanation: >-
      GWAS studies identify DNA repair gene modifiers influencing onset via
      somatic CAG expansion.
  - reference: PMID:33579859
    reference_title: "DNA Repair in Huntington's Disease and Spinocerebellar Ataxias: Somatic Instability and Alternative Hypotheses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Validation of leads including the mismatch repair protein MSH3, and
      interstrand cross-link repair protein FAN1, suggest the mechanism is driven
      by somatic CAG instability, which is supported by the protective effect of
      CAA substitutions in the CAG tract.
    explanation: >-
      Validates MSH3 and FAN1 as key mediators of somatic CAG instability.
  - reference: PMID:41130308
    reference_title: "Inhibiting Cytosine-Adenine-Guanine (CAG) repeat expansions as a therapeutic strategy for Huntington's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Somatic expansion of the CAG repeat length, beyond the inherited length, has
      been associated with hastening the onset of symptoms compared to that predicted
      from the germline length.
    explanation: >-
      Confirms somatic expansion accelerates onset beyond germline prediction.
  downstream:
  - target: Medium Spiny Neuron Degeneration
    description: >-
      Somatic expansion in striatal neurons exacerbates local protein toxicity
      and accelerates neuronal death.
- name: Mutant Huntingtin Protein Aggregation
  conforms_to: "polyglutamine_expansion_proteotoxicity#Misfolded Polyglutamine Protein Aggregation"
  description: >-
    The expanded polyglutamine tract causes mutant huntingtin to misfold and form
    intracellular aggregates (inclusion bodies) in neurons. These aggregates disrupt
    proteostasis, sequester essential cellular proteins including transcription factors
    (CBP, Sp1, TFIID, REST/NRSF), and interfere with transcriptional regulation,
    axonal transport, and synaptic function. Aberrant proteolytic cleavage by caspase-6
    generates toxic N-terminal fragments that accumulate in the nucleus.
  biological_processes:
  - preferred_term: Protein aggregation
    term:
      id: GO:0070841
      label: inclusion body assembly
  evidence:
  - reference: PMID:18992820
    reference_title: "Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Cleavage of huntingtin by caspase-6 at amino acid 586 is a crucial event
      in the pathogenesis of HD. Nuclear localization of huntingtin is also an
      important marker of HD and preventing or delaying its nuclear accumulation
      is protective in disease models.
    explanation: >-
      Demonstrates caspase-6 cleavage generates toxic N-terminal fragments and
      their nuclear accumulation drives pathogenesis.
  - reference: PMID:41233526
    reference_title: "Huntington disease: somatic expansion, pathobiology and therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although Huntington disease has long been viewed as a consequence of
      age-dependent toxicity from mutant huntingtin, genome-wide association
      studies have identified genetic modifiers, mostly DNA repair genes, that
      significantly influence disease onset and progression.
    explanation: >-
      Confirms the established view that mutant huntingtin protein toxicity
      is central to HD pathogenesis.
  downstream:
  - target: Medium Spiny Neuron Degeneration
    description: >-
      Mutant huntingtin aggregates and toxic fragments cause selective death of
      striatal medium spiny neurons.
  - target: Transcriptional Dysregulation
    description: >-
      Nuclear mutant huntingtin and N-terminal fragments sequester transcription
      factors (Sp1, CBP, REST/NRSF), dysregulating neuronal gene expression.
  - target: Excitotoxicity
    description: >-
      Mutant huntingtin sensitizes striatal neurons to NMDA-receptor-mediated
      glutamatergic excitotoxicity.
  - target: Mitochondrial Dysfunction
    description: >-
      Mutant huntingtin impairs mitochondrial bioenergetics, contributing to
      oxidative stress and energy failure.
- name: Medium Spiny Neuron Degeneration
  conforms_to: "polyglutamine_expansion_proteotoxicity#Selective Neuronal Dysfunction and Loss"
  description: >-
    GABAergic medium spiny neurons (MSNs) in the caudate nucleus and putamen are
    selectively vulnerable in HD. Indirect pathway MSNs expressing enkephalin and
    D2 dopamine receptors are affected earliest, followed by direct pathway MSNs.
    This selective vulnerability involves excitotoxicity from corticostriatal
    glutamatergic inputs, mitochondrial dysfunction, impaired BDNF signaling, and
    naturally low levels of protective S421 phosphorylation in striatal neurons.
  cell_types:
  - preferred_term: Medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: Neuronal apoptosis
    term:
      id: GO:0006915
      label: apoptotic process
  - preferred_term: Glutamate excitotoxicity
    term:
      id: GO:0007215
      label: glutamate receptor signaling pathway
  - preferred_term: Impaired BDNF trophic support
    term:
      id: GO:0031547
      label: brain-derived neurotrophic factor receptor signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:41233526
    reference_title: "Huntington disease: somatic expansion, pathobiology and therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The disease leads to progressive motor, cognitive and psychiatric decline,
      primarily resulting from loss of medium spiny neurons in the striatum.
    explanation: >-
      Directly confirms MSN loss in the striatum as the primary cause of HD
      clinical manifestations.
  - reference: PMID:18992820
    reference_title: "Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Huntingtin is phosphorylated on serine-421 (S421) by the pro-survival
      signaling protein kinases Akt and SGK. Phosphorylation of huntingtin at S421
      is variable in different regions of the brain with the lowest levels observed
      in the striatum, which is further reduced by the mutation for Huntington
      disease (HD).
    explanation: >-
      Explains selective striatal vulnerability through naturally low levels of
      neuroprotective S421 phosphorylation in the striatum.
  - reference: PMID:38427495
    reference_title: "Mono- and Biallelic Inactivation of Huntingtin Gene in Patient-Specific Induced Pluripotent Stem Cells Reveal HTT Roles in Striatal Development and Neuronal Functions."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      HTT loss or mutation has impacts on neuro-epithelial and striatal neurons
      maturation, and on basal DNA damage and BDNF axonal transport in post-mitotic
      neurons
    explanation: >-
      iPSC-derived models show HTT mutation impairs striatal neuron maturation
      and BDNF transport, contributing to selective vulnerability.
  downstream:
  - target: Chorea
  - target: Cognitive Decline
  - target: Memory Impairment
  - target: Bradyphrenia
  - target: Gait Disturbance
  - target: Gait Imbalance
  - target: Clumsiness
  - target: Poor Fine Motor Coordination
  - target: Abnormality of Eye Movement
  - target: Staring Gaze
  - target: Bradykinesia
  - target: Hypokinesia
  - target: Hyperreflexia
  - target: Involuntary Movements
  - target: Speech Articulation Difficulties
  - target: Oral-pharyngeal Dysphagia
- name: Neuroinflammation
  description: >-
    Reactive microglia and astrocytes contribute to HD pathogenesis through release
    of pro-inflammatory cytokines (IL-6, IL-8, TNF-alpha) and impaired glutamate
    buffering. Microglial activation occurs early, even before symptom onset, and
    correlates with disease progression. Peripheral immune dysregulation is also
    observed.
  cell_types:
  - preferred_term: Microglia
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: Neuroinflammatory response
    term:
      id: GO:0150076
      label: neuroinflammatory response
  evidence:
  - reference: PMID:39519337
    reference_title: "Neuroinflammatory Proteins in Huntington's Disease: Insights into Mechanisms, Diagnosis, and Therapeutic Implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Activation of the immune system and glial cell-mediated neuroinflammatory
      responses are early pathological features and have been found in all
      neurodegenerative diseases (NDDs), including HD.
    explanation: >-
      Dedicated HD neuroinflammation review confirming glial-mediated
      neuroinflammatory responses as early pathological features of HD.
  - reference: PMID:39519337
    reference_title: "Neuroinflammatory Proteins in Huntington's Disease: Insights into Mechanisms, Diagnosis, and Therapeutic Implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This review highlights the significantly elevated levels of inflammatory
      proteins and cellular markers observed in various HD animal models and HD
      patient tissues, emphasizing the critical roles of microglia, astrocytes,
      and oligodendrocytes in mediating neuroinflammation in HD.
    explanation: >-
      Establishes microglia and astrocytes as key mediators of neuroinflammation
      in HD with elevated inflammatory markers in patient tissues.
  downstream:
  - target: Medium Spiny Neuron Degeneration
    description: >-
      Neuroinflammatory activation contributes to progressive striatal neuronal
      injury in HD.
  - target: Abnormality of the Sense of Smell
- name: Excitotoxicity
  description: Overactivation of glutamate receptors leading to neuronal damage.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: chemical synaptic transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
  - preferred_term: excitatory postsynaptic potential
    term:
      id: GO:0060079
      label: excitatory postsynaptic potential
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  evidence:
  - reference: PMID:38776957
    reference_title: "Single nuclei RNA-seq reveals a medium spiny neuron glutamate excitotoxicity signature prior to the onset of neuronal death in an ovine Huntington's disease model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We have identified transcriptional upregulation of genes encoding N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors in medium spiny neurons, the cell type preferentially lost early in HD.
    explanation: The study identifies upregulation of glutamate receptors in medium spiny neurons, supporting the idea of excitotoxicity due to overactivation of these receptors leading to neuronal damage.
  - reference: PMID:1464368
    reference_title: "Mechanisms of excitotoxicity in neurologic diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Excitotoxicity refers to neuronal cell death caused by activation of excitatory amino acid receptors. A substantial body of evidence has implicated excitotoxicity as a mechanism of cell death in both acute and chronic neurologic diseases.
    explanation: This reference explains the concept of excitotoxicity and supports the idea that overactivation of glutamate receptors can lead to neuronal damage.
  - reference: PMID:7590394
    reference_title: "Elevated extracellular glutamate levels increased the formation of hydroxyl radical in the striatum of anesthetized rat."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Our results indicated that elevated glutamate concentrations (15 mM, 1.5 mM, and 150 microM glutamate in perfusing solutions) would significantly increased both the concentrations of 2,3 and 2,5 DHBA.
    explanation: The study provides direct evidence that elevated glutamate levels increase the formation of hydroxyl radicals, implying oxidative stress induced by excitotoxicity, which supports the statement.
  - reference: PMID:19805493
    reference_title: "Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Induction of striatal excitotoxicity in CB(2) receptor-deficient mice by quinolinic acid administration exacerbated brain oedema, microglial activation, proinflammatory-mediator state and medium-sized spiny neuron degeneration.
    explanation: This study shows that excitotoxicity induced in the striatum leads to medium spiny neuron degeneration, supporting the idea of excitotoxicity causing neuronal damage in Huntington's Disease.
  downstream:
  - target: Medium Spiny Neuron Degeneration
    description: >-
      Glutamate-receptor overactivation produces excitotoxic injury and death of
      striatal medium spiny neurons.
  - target: Seizures
- name: Mitochondrial Dysfunction
  conforms_to: "polyglutamine_expansion_proteotoxicity#Mitochondrial and Bioenergetic Dysfunction"
  description: Reduced efficiency of oxidative phosphorylation complexes, loss of mitochondrial membrane potential, and impaired mitochondrial DNA stability leading to bioenergetic failure.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
  - preferred_term: mitochondrion organization
    term:
      id: GO:0007005
      label: mitochondrion organization
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  evidence:
  - reference: PMID:19622387
    reference_title: "Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Nonetheless, it is becoming increasingly clear that alterations in mitochondrial function play key roles in the pathogenic processes in HD. The net result of these events is compromised energy metabolism and increased oxidative damage, which eventually contribute to neuronal dysfunction and death.
    explanation: Supports the pathophysiology entry by directly linking mitochondrial dysfunction in HD to compromised energy metabolism, oxidative damage, and neuronal death.
  - reference: PMID:23602910
    reference_title: "PGC-1alpha, mitochondrial dysfunction, and Huntington's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: There is strong evidence that mitochondrial dysfunction results in neurodegeneration and may contribute to the pathogenesis of Huntington's disease (HD). Studies over the past few years have implicated an impaired function of peroxisome proliferator-activated receptor (PPAR)-gamma coactivator-1alpha (PGC-1alpha), a transcriptional master coregulator of mitochondrial biogenesis, metabolism, and antioxidant defenses, in causing mitochondrial dysfunction in HD.
    explanation: Supports the mitochondrial dysfunction mechanism by connecting impaired PGC-1alpha activity to defective mitochondrial biogenesis, metabolism, and antioxidant defense in HD.
  downstream:
  - target: Medium Spiny Neuron Degeneration
    description: >-
      Bioenergetic failure and oxidative damage contribute to degeneration of
      energy-demanding striatal medium spiny neurons.
  - target: Weight Loss
  - target: Generalized Muscle Weakness
- name: D2 Receptor Medium Spiny Neuron Selective Vulnerability
  conforms_to: "polyglutamine_expansion_proteotoxicity#Selective Neuronal Dysfunction and Loss"
  description: D2 receptor-expressing medium spiny neurons show earlier huntingtin aggregation and greater sensitivity to CAG somatic instability compared to D1 receptor-expressing neurons.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: protein aggregation
    term:
      id: GO:0070841
      label: inclusion body assembly
  - preferred_term: synaptic transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
  downstream:
  - target: Medium Spiny Neuron Degeneration
    description: >-
      Indirect-pathway D2 medium spiny neurons show earliest aggregation and
      selective vulnerability, contributing to striatal neuron loss.
  - target: Dystonia
  - target: Myoclonus
- name: Transcriptional Dysregulation
  conforms_to: "polyglutamine_expansion_proteotoxicity#Transcriptional Dysregulation"
  description: Mutant huntingtin disrupts transcriptional regulation through sequestration of transcription factors including Sp1, CBP, and REST/NRSF, leading to widespread downregulation of neuronal genes including BDNF.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: regulation of transcription by RNA polymerase II
    term:
      id: GO:0006357
      label: regulation of transcription by RNA polymerase II
  - preferred_term: chromatin remodeling
    term:
      id: GO:0006338
      label: chromatin remodeling
  evidence:
  - reference: PMID:11839795
    reference_title: "Interaction of Huntington disease protein with transcriptional activator Sp1."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In HD transgenic mice (R6/2) that express N-terminal-mutant huntingtin, Sp1 binds to the soluble form of mutant huntingtin but not to aggregated huntingtin.
    explanation: In vivo evidence from HD transgenic mice showing that Sp1 binds soluble mutant huntingtin, supporting the sequestration mechanism.
  - reference: PMID:11839795
    reference_title: "Interaction of Huntington disease protein with transcriptional activator Sp1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Mutant huntingtin inhibits the binding of nuclear Sp1 to the promoter of nerve growth factor receptor and suppresses its transcriptional activity in cultured cells.
    explanation: Cell culture experiments demonstrating that mutant huntingtin suppresses Sp1-regulated transcription.
  - reference: PMID:11264541
    reference_title: "Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain.
    explanation: HD cell culture models showing CBP depletion from its normal nuclear location and sequestration into polyglutamine aggregates.
  - reference: PMID:11264541
    reference_title: "Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain.
    explanation: HD transgenic mice confirming CBP sequestration into polyglutamine aggregates in vivo.
  - reference: PMID:11264541
    reference_title: "Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain.
    explanation: Human HD postmortem brain tissue showing CBP depletion and sequestration into polyglutamine aggregates.
  - reference: PMID:12881722
    reference_title: "Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: aberrant accumulation of REST/NRSF in the nucleus is present in Huntington disease. We show that wild-type huntingtin coimmunoprecipitates with REST/NRSF and that less immunoprecipitated material is found in brain tissue with Huntington disease.
    explanation: Human postmortem brain data showing aberrant nuclear REST/NRSF accumulation and reduced huntingtin-REST/NRSF interaction in HD.
  - reference: PMID:12881722
    reference_title: "Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: loss of expression of NRSE-controlled neuronal genes is shown in cells, mice and human brain with Huntington disease.
    explanation: Mouse model data confirming loss of NRSE-controlled gene expression in HD, corroborating the REST/NRSF dysregulation mechanism.
  - reference: PMID:12881722
    reference_title: "Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Wild-type huntingtin inhibits the silencing activity of NRSE, increasing transcription of BDNF. We show that this effect occurs through cytoplasmic sequestering of repressor element-1 transcription factor/neuron restrictive silencer factor (REST/NRSF), the transcription factor that binds to NRSE.
    explanation: Cell-based experiments showing wild-type huntingtin sequesters REST/NRSF in the cytoplasm to permit BDNF transcription, a function lost with the mutant protein.
  downstream:
  - target: Mitochondrial Dysfunction
    description: Reduced transcription of PGC-1alpha-dependent mitochondrial and antioxidant programs drives downstream bioenergetic failure.
    hypothesis_groups:
    - canonical_transcriptional_dysregulation
    - canonical_mitochondrial_bioenergetic_failure
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - reduced PGC-1alpha activity
    - impaired mitochondrial biogenesis and antioxidant defense
    evidence:
    - reference: PMID:23602910
      reference_title: "PGC-1alpha, mitochondrial dysfunction, and Huntington's disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Studies over the past few years have implicated an impaired function of peroxisome proliferator-activated receptor (PPAR)-gamma coactivator-1alpha (PGC-1alpha), a transcriptional master coregulator of mitochondrial biogenesis, metabolism, and antioxidant defenses, in causing mitochondrial dysfunction in HD.
      explanation: Provides the missing causal bridge from transcriptional dysregulation to mitochondrial failure via impaired PGC-1alpha programs.
  - target: Medium Spiny Neuron Degeneration
    description: >-
      Loss of neuronal maintenance and survival gene programs (including BDNF)
      contributes to medium spiny neuron degeneration.
  - target: Depression
  - target: Anxiety
  - target: Agitation
  - target: Aggressive Behavior
  - target: Compulsive Behaviors
  - target: Disinhibition
  - target: Irritability
  - target: Hallucinations
  - target: Apathy
  - target: Delusion
  - target: Hostility
  - target: Abnormal Libido
  - target: Sleep Disturbances
mechanistic_hypotheses:
- hypothesis_group_id: canonical_toxic_gain_of_function
  hypothesis_label: Toxic Gain-of-Function (Polyglutamine Aggregation)
  status: CANONICAL
  description: >
    The expanded polyglutamine tract in mutant huntingtin confers a toxic
    gain-of-function through protein misfolding, oligomerization, and aggregation
    into inclusion bodies. This is the widely accepted primary disease mechanism,
    with polyQ expansion beyond the pathogenic threshold (~36 repeats) driving
    neurodegeneration predominantly in the striatum.
  notes: >-
    Retained as CANONICAL. The 2026 openscientist hypothesis-search report
    (kb/hypotheses/Huntingtons_Disease/canonical_toxic_gain_of_function)
    reviewed 81 papers and found the gain-of-function model robustly
    validated, but identified three critical refinements: (1) **somatic
    CAG repeat instability** driven by MMR genes (MSH3, MSH2, PMS1, MLH1,
    FAN1) is an upstream amplifier that expands repeats far beyond the
    inherited length in vulnerable striatal MSNs — inherited repeat length
    is necessary but not sufficient for toxicity; (2) gain-of-function
    operates alongside **loss of normal HTT function** (aggregates
    sequester wild-type HTT) rather than independently; (3) RNA-level
    toxicity from expanded CAG repeats is an additional pathogenic layer
    independent of protein aggregation. The first-generation HTT-lowering
    trials' disappointing results also signal that simple mHTT removal is
    insufficient and reinforce the multi-layered model.
  evidence:
  - reference: PMID:22180703
    reference_title: "The biological function of the Huntingtin protein and its relevance to Huntington's Disease pathology."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: It is caused by expansion of a polyglutamine tract within the N-terminal domain of the Huntingtin protein. The mutation confers a toxic gain-of-function phenotype, resulting in neurodegeneration that is most severe in the striatum.
    explanation: Explicitly names the toxic gain-of-function phenotype as the consequence of polyQ expansion and links it to striatal neurodegeneration.
  - reference: PMID:25336039
    reference_title: "Polyglutamine Aggregation in Huntington Disease: Does Structure Determine Toxicity?"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The mutational expansion of polyglutamine beyond a critical length produces a toxic gain of function in huntingtin and results in neuronal death. In the course of the disease, expanded huntingtin is proteolyzed, becomes abnormally folded, and accumulates in oligomers, fibrils, and microscopic inclusions.
    explanation: Directly states the toxic gain-of-function framing and details the aggregation cascade from proteolysis through misfolding to inclusion body formation.
  - reference: PMID:41233526
    reference_title: "Huntington disease: somatic expansion, pathobiology and therapeutics."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "These findings point to somatic CAG repeat expansions"
    explanation: >
      Major review reframes HD pathogenesis: somatic CAG repeat expansion
      driven by DNA repair (MMR) gene activity is now recognized as a
      rate-limiting upstream process that determines disease onset and
      progression — qualifying the simple gain-of-function model with a
      necessary upstream-amplifier step.
  - reference: PMID:22970194
    reference_title: "Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington's disease knock-in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "MSN-specific deletion of Msh2"
    explanation: >
      MSN-specific Msh2 deletion eliminates striatal HTT CAG expansions
      and dramatically inhibits intranuclear huntingtin inclusions —
      providing direct genetic evidence that somatic expansion in MSNs
      is a critical step in the toxic gain-of-function pathway.
  - reference: PMID:39938516
    reference_title: "Distinct mismatch-repair complex genes set neuronal CAG-repeat expansion rate to drive selective pathogenesis in HD mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Msh3 and Pms1 drive fast somatic mHtt CAG-expansion"
    explanation: >
      Msh3 deficiency in HD knockin mice eliminates striatal CAG
      expansions, keeps somatic MSN repeat length below the ~150-repeat
      aggregation threshold, and corrects synaptic/astrocytic/locomotor
      defects — establishing somatic expansion as a causal upstream step
      in striatal pathogenesis.
  - reference: PMID:37177784
    reference_title: "Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington's disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "siRNA-mediated silencing of Msh3 effectively blocked CAG-repeat expansion in the"
    explanation: >
      Therapeutic proof-of-concept: di-valent siRNA targeting MSH3 blocks
      somatic CAG expansion in the striatum of HD mouse models without
      affecting other MMR functions, validating somatic expansion as a
      tractable therapeutic target downstream of the canonical
      gain-of-function mutation.
- hypothesis_group_id: canonical_transcriptional_dysregulation
  hypothesis_label: Transcriptional Dysregulation
  status: CANONICAL
  description: >
    Mutant huntingtin disrupts transcriptional regulation by sequestering key
    transcription factors and co-activators (Sp1, CBP, REST/NRSF), leading to
    widespread downregulation of neuronal survival genes including BDNF. This
    is a canonical downstream mechanistic layer in HD, linking mutant huntingtin
    protein interactions to loss of neuronal maintenance programs.
  evidence:
  - reference: PMID:11839795
    reference_title: "Interaction of Huntington disease protein with transcriptional activator Sp1."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In HD transgenic mice (R6/2) that express N-terminal-mutant huntingtin, Sp1 binds to the soluble form of mutant huntingtin but not to aggregated huntingtin.
    explanation: In vivo evidence from HD transgenic mice showing that Sp1 binds soluble mutant huntingtin, supporting the sequestration mechanism.
  - reference: PMID:11839795
    reference_title: "Interaction of Huntington disease protein with transcriptional activator Sp1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Mutant huntingtin inhibits the binding of nuclear Sp1 to the promoter of nerve growth factor receptor and suppresses its transcriptional activity in cultured cells.
    explanation: Cell culture experiments demonstrating that mutant huntingtin suppresses Sp1-regulated transcription.
  - reference: PMID:11264541
    reference_title: "Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain.
    explanation: HD cell culture models showing CBP depletion from its normal nuclear location and sequestration into polyglutamine aggregates.
  - reference: PMID:11264541
    reference_title: "Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain.
    explanation: HD transgenic mice confirming CBP sequestration into polyglutamine aggregates in vivo.
  - reference: PMID:11264541
    reference_title: "Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain.
    explanation: Human HD postmortem brain tissue showing CBP depletion and sequestration into polyglutamine aggregates.
  - reference: PMID:12881722
    reference_title: "Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: aberrant accumulation of REST/NRSF in the nucleus is present in Huntington disease. We show that wild-type huntingtin coimmunoprecipitates with REST/NRSF and that less immunoprecipitated material is found in brain tissue with Huntington disease.
    explanation: Human postmortem brain data showing aberrant nuclear REST/NRSF accumulation and reduced huntingtin-REST/NRSF interaction in HD.
  - reference: PMID:12881722
    reference_title: "Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: loss of expression of NRSE-controlled neuronal genes is shown in cells, mice and human brain with Huntington disease.
    explanation: Mouse model data confirming loss of NRSE-controlled gene expression in HD, corroborating the REST/NRSF dysregulation mechanism.
  - reference: PMID:12881722
    reference_title: "Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Wild-type huntingtin inhibits the silencing activity of NRSE, increasing transcription of BDNF. We show that this effect occurs through cytoplasmic sequestering of repressor element-1 transcription factor/neuron restrictive silencer factor (REST/NRSF), the transcription factor that binds to NRSE.
    explanation: Cell-based experiments showing wild-type huntingtin sequesters REST/NRSF in the cytoplasm to permit BDNF transcription, a function lost with the mutant protein.
- hypothesis_group_id: canonical_mitochondrial_bioenergetic_failure
  hypothesis_label: Mitochondrial Dysfunction and Bioenergetic Failure
  status: CANONICAL
  description: >
    Mutant huntingtin impairs mitochondrial function through reduced oxidative
    phosphorylation complex activity, disrupted calcium homeostasis, and
    transcriptional repression of PGC-1alpha. This is a canonical convergent
    mechanism in HD that links transcriptional dysregulation and mutant huntingtin
    stress to bioenergetic failure, oxidative damage, and neuronal death,
    particularly in energy-demanding striatal medium spiny neurons.
  notes: >-
    Retained as CANONICAL but reframed as a **downstream convergent
    mediator** rather than an independent initiating event. The 2026
    openscientist hypothesis-search report
    (kb/hypotheses/Huntingtons_Disease/canonical_mitochondrial_bioenergetic_failure)
    reviewed 76 papers and identified three refinements: (1) the
    transcriptional-repression-of-PGC-1α pathway (PMID:17018277) is the
    strongest mechanistic link, validated by genetic and rescue
    experiments; (2) the "direct mHTT-mitochondria interaction" model is
    challenged by isolated-mitochondria studies, shifting emphasis toward
    indirect transcription-mediated mechanisms; (3) GWAS overwhelmingly
    implicate DNA-repair/somatic-expansion genes — not mitochondrial
    genes — as rate-limiting modifiers, positioning mitochondrial
    dysfunction as a downstream amplifier rather than an upstream driver.
    Failed clinical trials of mitochondrial-targeting agents (CoQ10,
    creatine) are consistent with this reframing. Bioenergetic failure
    critically synergizes with NMDAR-mediated excitotoxicity through ATP
    loss and Mg²⁺-block removal, creating a feedforward loop in
    energy-demanding striatal MSNs.
  evidence:
  - reference: PMID:17018277
    reference_title: "Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "mutant huntingtin causes disruption of mitochondrial function by inhibiting expression of PGC-1alpha"
    explanation: >
      Identifies PGC-1α transcriptional repression as the strongest
      mechanistic link from mHTT to mitochondrial dysfunction. PGC-1α KO
      crossbred with HD KI exacerbates striatal neurodegeneration; PGC-1α
      restoration via lentivirus is neuroprotective in HD mice — direct
      causal validation of the canonical pathway.
  - reference: PMID:19622387
    reference_title: "Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Nonetheless, it is becoming increasingly clear that alterations in mitochondrial function play key roles in the pathogenic processes in HD. The net result of these events is compromised energy metabolism and increased oxidative damage, which eventually contribute to neuronal dysfunction and death.
    explanation: Frames mitochondrial dysfunction as a key pathogenic mechanism linking compromised energy metabolism and oxidative damage to neuronal death.
  - reference: PMID:23602910
    reference_title: "PGC-1alpha, mitochondrial dysfunction, and Huntington's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: There is strong evidence that mitochondrial dysfunction results in neurodegeneration and may contribute to the pathogenesis of Huntington's disease (HD). Studies over the past few years have implicated an impaired function of peroxisome proliferator-activated receptor (PPAR)-gamma coactivator-1alpha (PGC-1alpha), a transcriptional master coregulator of mitochondrial biogenesis, metabolism, and antioxidant defenses, in causing mitochondrial dysfunction in HD.
    explanation: Links PGC-1alpha impairment to mitochondrial dysfunction in HD, connecting transcriptional dysregulation of mitochondrial biogenesis genes to bioenergetic failure.
- hypothesis_group_id: alternative_excitotoxicity
  hypothesis_label: NMDA Receptor-Mediated Excitotoxicity
  status: ALTERNATIVE
  description: >
    Historical but still supported superimposed model proposing that mutant
    huntingtin and corticostriatal circuit dysfunction enhance NMDA receptor-mediated
    excitotoxicity in striatal medium spiny neurons. This hypothesis is best viewed
    as a selective-vulnerability amplifier rather than the sole initiating lesion.
  evidence:
  - reference: PMID:17188796
    reference_title: "N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Many lines of evidence support a role for neuronal damage arising as a result of excessive activation of glutamate receptors by excitatory amino acids in the pathogenesis of Huntington disease. The N-methyl-d-aspartate subclass of ionotropic glutamate receptors (NMDARs) is more selective and effective than the other subclasses in mediating this damage.
    explanation: Comprehensive review establishing NMDAR-mediated excitotoxicity as a key pathogenic mechanism in HD with evidence from human tissue, animal models, and cell-based systems.
  - reference: PMID:19279257
    reference_title: "In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: This is the first direct in vivo evidence of NR2B-NMDAR-mediated excitotoxicity in the context of HD. Our results are consistent with previous suggestions that direct and/or indirect interactions of mutant huntingtin with NMDARs are a proximate cause of neurodegeneration in HD.
    explanation: Provides the first direct in vivo genetic evidence for the excitotoxicity hypothesis by showing exacerbated striatal neurodegeneration when NR2B-NMDAR subunits are overexpressed in an HD mouse model.
phenotypes:
- name: Chorea
  category: Clinical
  frequency: VERY_FREQUENT
  description: >-
    Involuntary, irregular, dance-like movements that are the hallmark motor feature
    of adult-onset HD. Chorea typically begins subtly and worsens over time before
    giving way to rigidity and bradykinesia in advanced stages.
  phenotype_term:
    preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  evidence:
  - reference: PMID:38861215
    reference_title: "Huntington's Disease: Latest Frontiers in Therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HD is characterized by the presence of chorea, alongside other hyperkinesia,
      parkinsonism and a combination of cognitive and behavioural features.
    explanation: >-
      Confirms chorea alongside other hyperkinesias as a characteristic feature of HD.
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002072 | Chorea | Very frequent (99-80%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies chorea as a very frequent
      Huntington disease phenotype.
- name: Cognitive Decline
  category: Clinical
  frequency: VERY_FREQUENT
  description: >-
    Progressive cognitive impairment affecting executive function, attention,
    psychomotor speed, and visuospatial skills, eventually progressing to subcortical
    dementia. Cognitive changes may precede motor onset by 10-15 years.
  phenotype_term:
    preferred_term: Progressive cognitive decline
    term:
      id: HP:0001268
      label: Mental deterioration
  evidence:
  - reference: PMID:40874597
    reference_title: "Therapeutic strategies for Huntington's disease: current approaches and future direction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Huntington's disease (HD) is an autosomal, progressive, dominant inherited
      neurological disorder characterized by motor dysfunction, cognitive decline,
      and psychiatric symptoms.
    explanation: >-
      Confirms cognitive decline as one of the three cardinal features of HD.
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001268 | Mental deterioration | Very frequent (99-80%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies mental deterioration as a
      very frequent Huntington disease phenotype.
- name: Depression
  category: Clinical
  frequency: FREQUENT
  description: >-
    Depressive symptoms are a common psychiatric manifestation of Huntington
    disease and may precede motor onset.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: PMID:38861215
    reference_title: "Huntington's Disease: Latest Frontiers in Therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HD is characterized by the presence of chorea, alongside other hyperkinesia,
      parkinsonism and a combination of cognitive and behavioural features.
    explanation: >-
      Confirms behavioral features as a core component of the HD clinical triad.
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000716 | Depression | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies depression as a frequent
      Huntington disease phenotype.
- name: Anxiety
  category: Clinical
  frequency: FREQUENT
  description: >-
    Anxiety is a frequent psychiatric manifestation of Huntington disease.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:38861215
    reference_title: "Huntington's Disease: Latest Frontiers in Therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HD is characterized by the presence of chorea, alongside other hyperkinesia,
      parkinsonism and a combination of cognitive and behavioural features.
    explanation: >-
      Confirms behavioral features as a core component of the HD clinical triad.
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000739 | Anxiety | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies anxiety as a frequent
      Huntington disease phenotype.
- name: Agitation
  category: Clinical
  frequency: FREQUENT
  description: >-
    Agitation is a frequent behavioral manifestation in the Orphanet Huntington
    disease phenotype profile.
  phenotype_term:
    preferred_term: Agitation
    term:
      id: HP:0000713
      label: Agitation
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000713 | Agitation | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies agitation as a frequent
      Huntington disease phenotype.
- name: Aggressive Behavior
  category: Clinical
  frequency: FREQUENT
  description: >-
    Aggressive behavior is a frequent behavioral manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Aggressive behavior
    term:
      id: HP:0000718
      label: Aggressive behavior
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000718 | Aggressive behavior | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies aggressive behavior as a
      frequent Huntington disease phenotype.
- name: Compulsive Behaviors
  category: Clinical
  frequency: FREQUENT
  description: >-
    Compulsive behaviors are frequent behavioral manifestations in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Compulsive behaviors
    term:
      id: HP:0000722
      label: Compulsive behaviors
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000722 | Compulsive behaviors | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies compulsive behaviors as a
      frequent Huntington disease phenotype.
- name: Disinhibition
  category: Clinical
  frequency: FREQUENT
  description: >-
    Disinhibition is a frequent behavioral manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Disinhibition
    term:
      id: HP:0000734
      label: Disinhibition
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000734 | Disinhibition | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies disinhibition as a frequent
      Huntington disease phenotype.
- name: Irritability
  category: Clinical
  frequency: FREQUENT
  description: >-
    Irritability is a frequent psychiatric manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Irritability
    term:
      id: HP:0000737
      label: Irritability
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000737 | Irritability | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies irritability as a frequent
      Huntington disease phenotype.
- name: Hallucinations
  category: Clinical
  frequency: FREQUENT
  description: >-
    Hallucinations are a frequent psychiatric manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Hallucinations
    term:
      id: HP:0000738
      label: Hallucinations
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000738 | Hallucinations | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies hallucinations as a frequent
      Huntington disease phenotype.
- name: Apathy
  category: Clinical
  frequency: FREQUENT
  description: >-
    Apathy is a frequent neuropsychiatric manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Apathy
    term:
      id: HP:0000741
      label: Apathy
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000741 | Apathy | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies apathy as a frequent
      Huntington disease phenotype.
- name: Delusion
  category: Clinical
  frequency: FREQUENT
  description: >-
    Delusion is a frequent psychiatric manifestation in the Orphanet Huntington
    disease phenotype profile.
  phenotype_term:
    preferred_term: Delusion
    term:
      id: HP:0000746
      label: Delusion
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000746 | Delusion | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies delusion as a frequent
      Huntington disease phenotype.
- name: Hostility
  category: Clinical
  frequency: FREQUENT
  description: >-
    Hostility is a frequent behavioral manifestation in the Orphanet Huntington
    disease phenotype profile.
  phenotype_term:
    preferred_term: Hostility
    term:
      id: HP:0031473
      label: Anger
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0031473 | Hostility | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies hostility as a frequent
      Huntington disease phenotype.
- name: Abnormal Libido
  category: Clinical
  frequency: FREQUENT
  description: >-
    Abnormal libido is a frequent behavioral manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Abnormal libido
    term:
      id: HP:0031845
      label: Abnormal libido
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0031845 | Abnormal libido | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies abnormal libido as a frequent
      Huntington disease phenotype.
- name: Memory Impairment
  category: Clinical
  frequency: FREQUENT
  description: >-
    Memory impairment is a frequent cognitive manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Memory impairment
    term:
      id: HP:0002354
      label: Memory impairment
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002354 | Memory impairment | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies memory impairment as a
      frequent Huntington disease phenotype.
- name: Bradyphrenia
  category: Clinical
  frequency: FREQUENT
  description: >-
    Bradyphrenia is a frequent cognitive manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Bradyphrenia
    term:
      id: HP:0031843
      label: Abnormally slow thought process
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0031843 | Bradyphrenia | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies bradyphrenia as a frequent
      Huntington disease phenotype.
- name: Gait Disturbance
  category: Clinical
  frequency: FREQUENT
  description: >-
    Abnormal gait is a common motor manifestation of Huntington disease,
    reflecting progressive basal ganglia and motor circuit dysfunction.
  phenotype_term:
    preferred_term: Gait disturbance
    term:
      id: HP:0001288
      label: Gait disturbance
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001288 | Gait disturbance | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies gait disturbance as a
      frequent Huntington disease phenotype.
- name: Gait Imbalance
  category: Clinical
  frequency: FREQUENT
  description: >-
    Gait imbalance is a frequent motor manifestation in the Orphanet Huntington
    disease phenotype profile.
  phenotype_term:
    preferred_term: Gait imbalance
    term:
      id: HP:0002141
      label: Gait imbalance
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002141 | Gait imbalance | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies gait imbalance as a frequent
      Huntington disease phenotype.
- name: Clumsiness
  category: Clinical
  frequency: FREQUENT
  description: >-
    Clumsiness is a frequent motor coordination manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Clumsiness
    term:
      id: HP:0002312
      label: Clumsiness
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002312 | Clumsiness | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies clumsiness as a frequent
      Huntington disease phenotype.
- name: Poor Fine Motor Coordination
  category: Clinical
  frequency: FREQUENT
  description: >-
    Poor fine motor coordination is a frequent motor manifestation in the
    Orphanet Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Poor fine motor coordination
    term:
      id: HP:0007010
      label: Poor fine motor coordination
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007010 | Poor fine motor coordination | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies poor fine motor coordination
      as a frequent Huntington disease phenotype.
- name: Abnormality of Eye Movement
  category: Clinical
  frequency: FREQUENT
  description: >-
    Abnormal eye movements are frequent neurologic manifestations in the
    Orphanet Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Abnormality of eye movement
    term:
      id: HP:0000496
      label: Abnormality of eye movement
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000496 | Abnormality of eye movement | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies abnormality of eye movement
      as a frequent Huntington disease phenotype.
- name: Staring Gaze
  category: Clinical
  frequency: FREQUENT
  description: >-
    Staring gaze is a frequent ocular-motor manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Staring gaze
    term:
      id: HP:0025401
      label: Staring gaze
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0025401 | Staring gaze | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies staring gaze as a frequent
      Huntington disease phenotype.
- name: Bradykinesia
  category: Clinical
  frequency: FREQUENT
  description: >-
    Slowness of movement can accompany or follow hyperkinetic features,
    especially in juvenile-onset or later-stage Huntington disease.
  phenotype_term:
    preferred_term: Bradykinesia
    term:
      id: HP:0002067
      label: Bradykinesia
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002067 | Bradykinesia | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies bradykinesia as a frequent
      Huntington disease phenotype.
- name: Hypokinesia
  category: Clinical
  frequency: FREQUENT
  description: >-
    Hypokinesia is a frequent hypokinetic motor manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Hypokinesia
    term:
      id: HP:0002375
      label: Hypokinesia
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002375 | Hypokinesia | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies hypokinesia as a frequent
      Huntington disease phenotype.
- name: Hyperreflexia
  category: Clinical
  frequency: VERY_FREQUENT
  description: >-
    Increased deep tendon reflexes are included in Orphanet's very frequent HPO
    phenotype annotations for Huntington disease.
  phenotype_term:
    preferred_term: Hyperreflexia
    term:
      id: HP:0001347
      label: Hyperreflexia
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001347 | Hyperreflexia | Very frequent (99-80%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies hyperreflexia as a very
      frequent Huntington disease phenotype.
- name: Dystonia
  category: Clinical
  frequency: FREQUENT
  description: >-
    Sustained muscle contractions causing abnormal postures, particularly prominent
    in juvenile-onset HD and in later stages of adult-onset disease.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001332 | Dystonia | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies dystonia as a frequent
      Huntington disease phenotype.
- name: Myoclonus
  category: Clinical
  frequency: FREQUENT
  description: >-
    Myoclonus is a frequent motor manifestation in the Orphanet Huntington
    disease phenotype profile.
  phenotype_term:
    preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001336 | Myoclonus | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies myoclonus as a frequent
      Huntington disease phenotype.
- name: Involuntary Movements
  category: Clinical
  frequency: FREQUENT
  description: >-
    Involuntary movements are a frequent motor manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Involuntary movements
    term:
      id: HP:0004305
      label: Involuntary movements
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0004305 | Involuntary movements | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies involuntary movements as a
      frequent Huntington disease phenotype.
- name: Weight Loss
  category: Clinical
  frequency: FREQUENT
  description: >-
    Progressive involuntary weight loss despite adequate caloric intake, related to
    hypermetabolic state from chorea, dysphagia, and central hypothalamic dysfunction.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001824 | Weight loss | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies weight loss as a frequent
      Huntington disease phenotype.
- name: Generalized Muscle Weakness
  category: Clinical
  frequency: FREQUENT
  description: >-
    Generalized muscle weakness is a frequent motor manifestation in the
    Orphanet Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Generalized muscle weakness
    term:
      id: HP:0003324
      label: Generalized muscle weakness
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003324 | Generalized muscle weakness | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies generalized muscle weakness
      as a frequent Huntington disease phenotype.
- name: Abnormality of the Sense of Smell
  category: Clinical
  frequency: FREQUENT
  description: >-
    Abnormality of the sense of smell is a frequent sensory manifestation in the
    Orphanet Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Abnormality of the sense of smell
    term:
      id: HP:0004408
      label: Abnormality of the sense of smell
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0004408 | Abnormality of the sense of smell | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies abnormality of the sense of
      smell as a frequent Huntington disease phenotype.
- name: Speech Articulation Difficulties
  category: Clinical
  frequency: FREQUENT
  description: >-
    Progressive speech difficulty due to impaired motor control of muscles
    involved in speech production.
  phenotype_term:
    preferred_term: Speech articulation difficulties
    term:
      id: HP:0009088
      label: Speech articulation difficulties
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0009088 | Speech articulation difficulties | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies speech articulation
      difficulties as a frequent Huntington disease phenotype.
- name: Oral-pharyngeal Dysphagia
  category: Clinical
  frequency: OCCASIONAL
  description: >-
    Difficulty swallowing that increases aspiration risk. Aspiration pneumonia is a
    leading cause of death in HD.
  phenotype_term:
    preferred_term: Oral-pharyngeal dysphagia
    term:
      id: HP:0200136
      label: Oral-pharyngeal dysphagia
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0200136 | Oral-pharyngeal dysphagia | Occasional (29-5%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies oral-pharyngeal dysphagia as
      an occasional Huntington disease phenotype.
- name: Seizures
  category: Clinical
  subtype: Juvenile HD
  description: >-
    Seizures occur in approximately 25-40% of juvenile-onset HD patients
    but are uncommon in adult-onset disease.
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "HP:0001250 | Seizure | Frequent (79-30%)"
    explanation: >-
      Orphanet records seizures as a frequent disease-level HPO annotation. This
      partially supports the seizure phenotype here, while this entry retains the
      juvenile-HD subtype context for clinical specificity.
- name: Sleep Disturbances
  category: Clinical
  description: >-
    Sleep disturbances are prevalent in HD, including periodic limb movements (35%),
    poor sleep quality (59%), excessive daytime sleepiness, and circadian rhythm
    disruption. Sleep medication use is reported in 29% of patients.
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:41722529
    reference_title: "What is the prevalence of sleep disturbances among people with Huntington disease and pre-manifest genetic expansion carriers? A systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Meta-analysed prevalence of objectively-measured sleep disturbances include:
      35% for periodic limb movements (PLM index>15/hour), 3% for REM sleep
      behaviour disorder, 5% for REM sleep without atonia, and 9% for
      sleep-disordered breathing (AHI>5/hour); and of self-reported measures: 29%
      for use of sleep medications, 59% for poor sleep quality (Pittsburgh sleep
      quality index), and 15% for excessive daytime sleepiness (Epworth sleepiness
      scale).
    explanation: >-
      Systematic review with meta-analysis quantifying the prevalence of multiple
      sleep disturbances in HD patients.
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "HP:0100785 | Insomnia | Occasional (29-5%)"
    explanation: >-
      Orphanet's insomnia annotation supports one component of the broader sleep
      disturbance phenotype.
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: PARTIAL
    evidence_source: OTHER
    snippet: "HP:0001262 | Excessive daytime somnolence | Occasional (29-5%)"
    explanation: >-
      Orphanet's excessive daytime somnolence annotation supports another
      component of the broader sleep disturbance phenotype.
biochemical:
- name: Neurofilament Light Chain (NfL)
  notes: >-
    Plasma and CSF neurofilament light chain is elevated in both pre-manifest
    and manifest HD. NfL meets evidentiary guidelines as a prognostic biomarker
    in premanifest HD and can detect changes in very early disease stages.
  evidence:
  - reference: PMID:41081429
    reference_title: "Systematic Review with Meta-Analysis of Biofluid Markers for Huntington's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Evidence for neurofilament light (NfL) is sufficient to meet evidentiary
      guidelines as a prognostic biomarker in preHD (ie, before clinical motor
      diagnosis).
    explanation: >-
      Systematic review with meta-analysis establishes NfL as a validated
      prognostic biomarker in pre-manifest HD.
  - reference: PMID:39891767
    reference_title: "Serum neurofilament light chain but not serum glial fibrillary acidic protein is a marker of early Huntington's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      sNfL levels differed significantly between preHD and early HD, and HC
      (all p values < 0.05)
    explanation: >-
      Confirms serum NfL can distinguish pre-manifest and early HD from
      healthy controls.
- name: Mutant Huntingtin Protein (mHTT)
  notes: >-
    Mutant huntingtin protein is quantifiable in cerebrospinal fluid and serves
    as a pharmacodynamic biomarker for HTT-lowering therapies.
  evidence:
  - reference: PMID:38861215
    reference_title: "Huntington's Disease: Latest Frontiers in Therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The possibility of quantifying mHTT in CSF, along with the development
      of an integrated biological staging system in HD are important innovations
      applicable to clinical trial design that enhance the drug development process.
    explanation: >-
      Highlights CSF mHTT quantification as a key innovation for HD clinical
      trial design.
- name: Elevated Neuronal Inclusions
  presence: Positive
  notes: Aggregates of mutant huntingtin protein found in neurons.
  evidence:
  - reference: PMID:22200539
    reference_title: "Protein aggregates in Huntington's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Here we will review the state of knowledge of HD, focusing especially on a hallmark pathological feature-intracellular aggregates of mutant Htt called inclusion bodies (IBs).
    explanation: The article discusses the presence of intracellular aggregates of mutant huntingtin, which are referred to as inclusion bodies, supporting the statement.
  - reference: PMID:38810948
    reference_title: "Evidence of mutant huntingtin and tau-related pathology within neuronal grafts in Huntington's disease cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We confirmed the presence of mHtt aggregates within grafts of all three cases as well as tau neuropil threads in the grafts of two of the three transplanted HD patients.
    explanation: The study confirms the presence of mutant huntingtin (mHtt) aggregates within neurons, supporting the statement.
  - reference: PMID:19172113
    reference_title: "Aggregation of expanded huntingtin in the brains of patients with Huntington disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: It is likely that the aggregates containing expanded huntingtin are toxic to neurons, but it remains to be determined whether the oligomer or the inclusion is the toxic species.
    explanation: The article mentions that aggregates containing expanded huntingtin are found in neurons, supporting the statement.
  - reference: PMID:27886014
    reference_title: "Embryonic Mutant Huntingtin Aggregate Formation in Mouse Models of Huntington's Disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Using highly sensitive immunohistochemical methods we have detected the appearance of diffuse aggregates during embryonic development in the R6/2 and YAC128 mouse models of HD.
    explanation: The study observes the formation of aggregates in neuronal cells during embryonic development in mouse models of HD, supporting the statement.
genetic:
- name: HTT
  association: Causative
  gene_term:
    preferred_term: HTT
    term:
      id: hgnc:4851
      label: HTT
  notes: >-
    The huntingtin gene on chromosome 4p16.3. CAG repeat expansion in exon 1
    beyond 36 repeats causes HD with full penetrance at 40+ repeats (reduced
    penetrance at 36-39). Normal alleles have 6-26 repeats; intermediate alleles
    (27-35) can expand to pathogenic range in offspring. The gene encodes huntingtin,
    a 3,144 amino acid scaffolding protein involved in vesicular transport,
    transcription, autophagy, and cell survival.
  evidence:
  - reference: PMID:41130308
    reference_title: "Inhibiting Cytosine-Adenine-Guanine (CAG) repeat expansions as a therapeutic strategy for Huntington's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Huntington's Disease (HD) became the first disease mapped to a single
      chromosome and associated with mutations in the huntingtin (HTT) gene,
      specifically expansions in the trinucleotide cytosine-adenine-guanine (CAG)
      within exon 1.
    explanation: >-
      Confirms the CAG repeat expansion in HTT exon 1 as the causative mutation.
  - reference: CGGV:assertion_617c18ee-9476-4bc0-b403-20bc55150c7c-2021-11-08T193955.489Z
    reference_title: "HTT / Huntington disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HTT | HGNC:4851 | Huntington disease | MONDO:0007739 | AD | Definitive"
    explanation: ClinGen classifies the HTT-Huntington disease gene-disease relationship as definitive with autosomal dominant inheritance.
- name: MSH3
  association: Modifier
  gene_term:
    preferred_term: MSH3
    term:
      id: hgnc:7326
      label: MSH3
  notes: >-
    DNA mismatch repair gene identified as a key genetic modifier of HD onset age
    through GWAS. MSH3 drives somatic CAG repeat expansion in striatal neurons;
    variants that reduce MSH3 activity delay onset. A major therapeutic target.
  evidence:
  - reference: PMID:33579859
    reference_title: "DNA Repair in Huntington's Disease and Spinocerebellar Ataxias: Somatic Instability and Alternative Hypotheses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Validation of leads including the mismatch repair protein MSH3, and
      interstrand cross-link repair protein FAN1, suggest the mechanism is driven
      by somatic CAG instability, which is supported by the protective effect of
      CAA substitutions in the CAG tract.
    explanation: >-
      Identifies MSH3 as a validated modifier driving somatic CAG instability.
- name: FAN1
  association: Modifier
  gene_term:
    preferred_term: FAN1
    term:
      id: hgnc:29170
      label: FAN1
  notes: >-
    Fanconi anemia-associated nuclease 1. FAN1 protects against somatic CAG expansion;
    variants that enhance FAN1 activity are associated with delayed onset of HD.
  evidence:
  - reference: PMID:33579859
    reference_title: "DNA Repair in Huntington's Disease and Spinocerebellar Ataxias: Somatic Instability and Alternative Hypotheses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Validation of leads including the mismatch repair protein MSH3, and
      interstrand cross-link repair protein FAN1, suggest the mechanism is driven
      by somatic CAG instability, which is supported by the protective effect of
      CAA substitutions in the CAG tract.
    explanation: >-
      Identifies FAN1 as a protective modifier against somatic CAG expansion.
- name: SLC2A3
  association: Modifier
  gene_term:
    preferred_term: SLC2A3
    term:
      id: hgnc:11007
      label: SLC2A3
  notes: >-
    Orphanet lists SLC2A3 as a modifying germline mutation association for
    Huntington disease.
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease (Orphanet structured-database record)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SLC2A3 | solute carrier family 2 member 3 | hgnc:11007 | Modifying germline mutation in"
    explanation: >-
      Orphanet's gene table lists SLC2A3 as a modifying germline mutation
      association for Huntington disease.
- name: MLH1
  association: Genetic Modifier
  notes: DNA mismatch repair gene; drives somatic CAG expansion and significantly affects disease onset age and progression.
- name: PMS1
  association: Genetic Modifier
  notes: DNA mismatch repair gene; influences somatic CAG repeat expansion.
- name: PMS2
  association: Genetic Modifier
  notes: DNA mismatch repair gene; influences somatic CAG repeat expansion.
- name: LIG1
  association: Genetic Modifier
  notes: DNA ligase gene; involved in DNA repair pathways that modulate somatic CAG instability.
- name: PPARGC1A
  association: Pathophysiological Role
  notes: PGC-1alpha gene; reduced expression contributes to bioenergetic failure and mitochondrial dysfunction in HD.
- name: SLC1A2
  association: Pathophysiological Role
  notes: EAAT2 glutamate transporter gene; impaired function contributes to excitotoxicity through reduced glutamate clearance.
- name: BDNF
  association: Pathophysiological Role
  notes: Brain-derived neurotrophic factor; impaired trophic signaling and transport from cortex to striatum contributes to neuronal vulnerability.
- name: NTRK2
  association: Pathophysiological Role
  notes: TrkB receptor gene; mediates BDNF signaling; impaired function contributes to reduced trophic support.
- name: DRD1
  association: Pathophysiological Role
  notes: Dopamine D1 receptor; marker of direct pathway medium spiny neurons.
- name: DRD2
  association: Pathophysiological Role
  notes: Dopamine D2 receptor; marker of indirect pathway medium spiny neurons which show earlier vulnerability and greater CAG instability.
- name: SQSTM1
  association: Pathophysiological Role
  notes: p62/SQSTM1 gene; autophagy adaptor protein; accumulation indicates autophagy-lysosomal pathway dysfunction.
treatments:
- name: Tetrabenazine
  description: >-
    Vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treatment
    of chorea in HD. Reduces dopamine signaling in the basal ganglia. Most effective
    of the three VMAT2 inhibitors for chorea control but associated with higher rates
    of sedation and carries a boxed warning for depression.
  treatment_term:
    preferred_term: Tetrabenazine for chorea
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tetrabenazine
      term:
        id: CHEBI:9467
        label: tetrabenazine
  evidence:
  - reference: PMID:41069601
    reference_title: "Efficacy and safety of vesicular monoamine transporter 2 inhibitors for Huntington's disease chorea based on network meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study suggests that three VMAT2 inhibitors are effective in ameliorating
      chorea symptoms in patients with Huntington's disease. Tetrabenazine is the
      most effective in controlling chorea, whereas valbenazine may be the optimal
      choice for patients with comorbid psychiatric symptoms.
    explanation: >-
      Network meta-analysis confirms tetrabenazine as the most effective VMAT2
      inhibitor for chorea symptom control.
  target_mechanisms:
  - target: D2 Receptor Medium Spiny Neuron Selective Vulnerability
    treatment_effect: MODULATES
    description: >-
      Tetrabenazine inhibits VMAT2, depleting presynaptic dopamine and reducing
      striatal dopaminergic drive to compensate for the loss of D2-receptor-bearing
      indirect-pathway medium spiny neurons that underlies HD chorea.
- name: Deutetrabenazine
  description: >-
    Deuterated form of tetrabenazine with improved pharmacokinetics and tolerability
    profile, approved for HD chorea. Twice-daily dosing with less CYP2D6 interaction
    and lower sedation risk than tetrabenazine.
  treatment_term:
    preferred_term: Deutetrabenazine for chorea
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:41069601
    reference_title: "Efficacy and safety of vesicular monoamine transporter 2 inhibitors for Huntington's disease chorea based on network meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study suggests that three VMAT2 inhibitors are effective in ameliorating
      chorea symptoms in patients with Huntington's disease. Tetrabenazine is the
      most effective in controlling chorea, whereas valbenazine may be the optimal
      choice for patients with comorbid psychiatric symptoms.
    explanation: >-
      Network meta-analysis confirms deutetrabenazine efficacy for HD chorea.
  target_mechanisms:
  - target: D2 Receptor Medium Spiny Neuron Selective Vulnerability
    treatment_effect: MODULATES
    description: >-
      Deutetrabenazine inhibits VMAT2, depleting presynaptic dopamine and reducing
      striatal dopaminergic drive to compensate for the loss of D2-receptor-bearing
      indirect-pathway medium spiny neurons that underlies HD chorea.
- name: Valbenazine
  description: >-
    Selective VMAT2 inhibitor approved in 2023 for HD chorea. Once-daily dosing
    with minimal CYP2D6 interaction. May be optimal for patients with comorbid
    psychiatric symptoms. Available in sprinkle formulation for patients with dysphagia.
  treatment_term:
    preferred_term: Valbenazine for chorea
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:41069601
    reference_title: "Efficacy and safety of vesicular monoamine transporter 2 inhibitors for Huntington's disease chorea based on network meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study suggests that three VMAT2 inhibitors are effective in ameliorating
      chorea symptoms in patients with Huntington's disease. Tetrabenazine is the
      most effective in controlling chorea, whereas valbenazine may be the optimal
      choice for patients with comorbid psychiatric symptoms.
    explanation: >-
      Network meta-analysis identifies valbenazine as optimal for patients with
      comorbid psychiatric symptoms.
  - reference: PMID:41069601
    reference_title: "Efficacy and safety of vesicular monoamine transporter 2 inhibitors for Huntington's disease chorea based on network meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      valbenazine ranked first in withdrawals due to AEs (0.735), serious adverse
      events (0.807), as well as in reducing both suicide (0.683) and suicidal
      ideation (0.748).
    explanation: >-
      In the network meta-analysis ranking (SUCRA), valbenazine was the most
      favorable VMAT2 inhibitor for tolerability and psychiatric-safety endpoints,
      including reduced suicide and suicidal ideation - relevant given the high
      suicide risk in Huntington disease and supporting valbenazine as the
      preferred agent for patients with comorbid psychiatric symptoms.
  target_mechanisms:
  - target: D2 Receptor Medium Spiny Neuron Selective Vulnerability
    treatment_effect: MODULATES
    description: >-
      Valbenazine selectively inhibits VMAT2, depleting presynaptic dopamine and
      reducing striatal dopaminergic drive to compensate for the loss of
      D2-receptor-bearing indirect-pathway medium spiny neurons that underlies HD chorea.
- name: HTT-Lowering Therapies
  description: >-
    Emerging disease-modifying approaches including antisense oligonucleotides (ASOs),
    splice modulators, and microRNA-based gene therapy targeting mutant huntingtin
    protein reduction. Allele-selective approaches that spare wild-type HTT are
    preferred after the tominersen trial showed non-selective lowering can cause harm.
  treatment_term:
    preferred_term: HTT-lowering gene therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:38861215
    reference_title: "Huntington's Disease: Latest Frontiers in Therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HD is living in an era of target-specific drug development with emphasis on
      the mechanisms related to mutant Huntingtin (HTT) protein. Examples include
      antisense oligonucleotides (ASO), splicing modifiers and microRNA molecules
      that aim to reduce the levels of mutant HTT protein.
    explanation: >-
      Reviews the current landscape of HTT-lowering therapeutic approaches.
  - reference: PMID:41090742
    reference_title: "Revolutionizing Huntington's Disease Treatment: Breakthroughs in AAV-Mediated Gene Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among emerging and novel treatments for central nervous system (CNS)
      disorders, gene therapy (GT), particularly using adeno-associated virus
      (AAV)-mediated gene delivery, holds great promise.
    explanation: >-
      Reviews AAV-mediated gene therapy as a promising approach for HD treatment.
  target_mechanisms:
  - target: HTT CAG Repeat Expansion
    treatment_effect: INHIBITS
    description: >-
      HTT-lowering ASOs, splice modulators, and microRNA-based therapies reduce
      the expression of mutant huntingtin, directly suppressing the root CAG
      repeat-expansion-driven toxicity at the mRNA and protein level.
  - target: Mutant Huntingtin Protein Aggregation
    treatment_effect: INHIBITS
    description: >-
      By lowering mutant HTT protein levels, these therapies reduce the
      substrate available for mHTT misfolding and nuclear and cytoplasmic
      aggregate formation.
- name: Somatic Expansion Inhibition
  description: >-
    Novel therapeutic paradigm targeting DNA mismatch repair machinery (particularly
    MSH3) to slow or halt somatic CAG repeat expansion in striatal neurons. Considered
    the most promising emerging strategy as it addresses the upstream DNA-level
    mechanism rather than downstream protein toxicity.
  treatment_term:
    preferred_term: Somatic expansion inhibitor therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:41233526
    reference_title: "Huntington disease: somatic expansion, pathobiology and therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      interventions to limit somatic repeat expansion might be effective across
      multiple repeat expansion diseases and, when combined with disease-specific
      approaches, such as huntingtin lowering in Huntington disease, might offer
      more effective and longer-lasting clinical benefits than either strategy in
      isolation.
    explanation: >-
      Supports somatic expansion inhibition as a promising combinatorial therapeutic
      strategy for HD and other repeat expansion disorders.
  target_mechanisms:
  - target: Somatic CAG Repeat Expansion
    treatment_effect: INHIBITS
    description: >-
      Inhibiting MSH3 and other mismatch repair factors slows or halts the
      somatic CAG repeat expansion that drives progressive striatal toxicity,
      targeting the upstream DNA-level mechanism rather than downstream protein
      aggregation.
- name: Human Neural Stem Cell Transplantation (hNSC-01)
  description: >-
    Investigational regenerative cell therapy in which good manufacturing
    practice (GMP)-grade human embryonic stem cell-derived neural stem cells
    (hNSC-01) are stereotactically implanted into the striatum. Rather than
    acting by neuronal replacement alone, the grafted cells are proposed to work
    through neuroprotection and trophic support (including BDNF), reconstruction
    of striatal synaptic circuitry, and reduction of mutant huntingtin
    accumulation. This is the cell-therapy approach being evaluated first-in-human
    in the UCI Health REGEN4HD trial (NCT07451613).
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: human neural stem cell transplantation
    term:
      id: MAXO:0000016
      label: cellular therapy
  target_phenotypes:
  - preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  - preferred_term: Progressive cognitive decline
    term:
      id: HP:0001268
      label: Mental deterioration
  evidence:
  - reference: PMID:29233555
    reference_title: "Human Neural Stem Cell Transplantation Rescues Functional Deficits in R6/2 and Q140 Huntington's Disease Mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Disease-modifying activity is suggested by the reduction of aberrant
      accumulation of mutant HTT protein and expression of brain-derived
      neurotrophic factor (BDNF) in both models.
    explanation: >-
      Preclinical study of the GMP-grade hNSC line that forms the basis for
      hNSC-01, transplanted into the striatum of R6/2 and Q140 HD mice, showed
      improved motor function, reduced mutant HTT accumulation, and increased
      BDNF, supporting a disease-modifying neurotrophic mechanism.
  - reference: clinicaltrials:NCT07451613
    reference_title: "Phase 1B/2A Study of the Safety and Tolerability of Human Neural Stem Cells for Huntington's Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "to determine whether an implantation of hNSC-01 is a safe and tolerable study intervention for Huntington's disease"
    explanation: >-
      The first-in-human REGEN4HD trial is evaluating intrastriatal hNSC-01
      implantation for safety and tolerability in early-stage HD.
  target_mechanisms:
  - target: Medium Spiny Neuron Degeneration
    treatment_effect: MODULATES
    description: >-
      Intrastriatal hNSC grafts provide trophic support (notably BDNF) and
      synaptic/circuit reconstruction intended to protect and functionally
      compensate for the vulnerable striatal medium spiny neurons whose
      degeneration drives HD motor and cognitive decline.
  - target: Mutant Huntingtin Protein Aggregation
    treatment_effect: INHIBITS
    description: >-
      In HD mouse models, hNSC transplantation reduced aberrant accumulation of
      mutant huntingtin, indicating a disease-modifying effect on mHTT
      proteostasis beyond simple cell replacement.
- name: AMT-130 (AAV5-miHTT Gene Therapy)
  description: >-
    One-time HTT-lowering gene therapy delivering an engineered microRNA (miHTT)
    via an adeno-associated virus serotype 5 (rAAV5) vector by MRI-guided
    stereotactic infusion into the caudate and putamen. The vector-expressed
    miHTT drives non-allele-selective (total) lowering of huntingtin mRNA and
    protein in striatal neurons. In the Phase 1/2 program (NCT04120493 /
    NCT05243017) the high dose showed slowing of clinical progression and lowered
    CSF neurofilament light chain, and a BLA submission is planned.
  therapeutic_modality: GENE_THERAPY
  treatment_term:
    preferred_term: AAV5-miHTT gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  target_phenotypes:
  - preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  - preferred_term: Progressive cognitive decline
    term:
      id: HP:0001268
      label: Mental deterioration
  evidence:
  - reference: PMID:30984798
    reference_title: "AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      AAV5-miHTT caused a dose-dependent and sustained HTT protein reduction with
      subsequent suppression of mutant HTT aggregate formation in the striatum
      and cortex.
    explanation: >-
      Preclinical study of the AAV5-miHTT construct underlying AMT-130 showing
      dose-dependent, sustained huntingtin lowering and reduced mutant HTT
      aggregation after intrastriatal delivery in HD mouse models.
  - reference: clinicaltrials:NCT04120493
    reference_title: "A Phase 1/2, Randomized, Double-Blind, Sham Control and Open-Label Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington's Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC)."
    explanation: >-
      ClinicalTrials.gov record for the first-in-human Phase 1/2 study of the
      rAAV5-miHTT gene therapy AMT-130 in early manifest Huntington's disease.
  target_mechanisms:
  - target: HTT CAG Repeat Expansion
    treatment_effect: INHIBITS
    description: >-
      The AAV5-delivered miHTT microRNA degrades huntingtin mRNA, lowering total
      (mutant and wild-type) huntingtin expression and thereby suppressing the
      downstream toxicity of the CAG-repeat-expanded transcript at its source.
  - target: Mutant Huntingtin Protein Aggregation
    treatment_effect: INHIBITS
    description: >-
      By reducing huntingtin mRNA, AMT-130 lowers mutant huntingtin protein
      levels, decreasing the substrate available for mHTT misfolding and
      aggregate formation in striatal neurons.
- name: Allele-Selective CRISPR/Cas9 HTT Inactivation
  description: >-
    Genome-editing strategy that permanently inactivates the expanded
    (mutant) HTT allele while sparing the wild-type allele. Allele selectivity is
    achieved by directing Cas9 to heterozygous, allele-specific single-nucleotide
    polymorphisms (SNPs) that create or destroy a CRISPR PAM motif on the mutant
    chromosome. Preclinical proof-of-concept in HD patient cells and a transgenic
    HD mouse model; not yet in clinical trials.
  therapeutic_modality: GENE_EDITING
  treatment_term:
    preferred_term: allele-selective genome editing
    term:
      id: MAXO:0001001
      label: gene therapy
  target_phenotypes:
  - preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  - preferred_term: Progressive cognitive decline
    term:
      id: HP:0001268
      label: Mental deterioration
  evidence:
  - reference: PMID:28129107
    reference_title: "CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "HEK293 cells, which are homozygous for the targeting SNPs (Figure 2B), were transfected with SpCas9 and sgRNA expression plasmids and genomic deletion assessed."
    explanation: >-
      In vitro demonstration of SNP-dependent, allele-selective CRISPR/Cas9
      excision of HTT in human cells homozygous for the targeting SNPs.
  - reference: PMID:28129107
    reference_title: "CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Interestingly, mouse Htt mRNA levels were also reduced on the injected
      hemisphere, although to a lesser degree than the human HTT allele.
    explanation: >-
      In vivo confirmation in BacHD transgenic mice (carrying the human HD allele
      with the targeting SNPs) that intrastriatal CRISPR/Cas9 editing lowers HTT
      expression on the injected hemisphere.
  target_mechanisms:
  - target: HTT CAG Repeat Expansion
    treatment_effect: INHIBITS
    description: >-
      Allele-selective CRISPR/Cas9 editing introduces inactivating breaks in the
      mutant HTT allele, permanently abolishing expression of the CAG-expanded
      transcript while leaving the wild-type allele intact.
- name: Human Dental Pulp Stem Cell Therapy (NestaCell)
  description: >-
    Investigational allogeneic cell therapy using intravenously infused human
    dental pulp stem cells (hDPSCs; NestaCell, formerly Cellavita HD). The
    rationale is neurotrophic support and modulation of neuroinflammation rather
    than direct neuronal replacement. A randomized, double-blind,
    placebo-controlled Phase II trial (NCT03252535) reported a favorable safety
    profile and significant improvements in motor and functional scores,
    supporting advancement to Phase III.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: human dental pulp stem cell therapy
    term:
      id: MAXO:0000016
      label: cellular therapy
  target_phenotypes:
  - preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  - preferred_term: Progressive cognitive decline
    term:
      id: HP:0001268
      label: Mental deterioration
  evidence:
  - reference: PMID:40770775
    reference_title: "Phase II trial of intravenous human dental pulp stem cell therapy for Huntington's disease: a randomized, double-blind, placebo-controlled study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Both doses significantly improved UHDRS-TMS compared to placebo (p =
      0.005), while the 2 million cells/kg group showed significant benefits in
      UHDRS-TFC (p = 0.011).
    explanation: >-
      Randomized, double-blind, placebo-controlled Phase II trial of allogeneic
      human dental pulp stem cells (NestaCell) showing significant motor
      (UHDRS-TMS) and functional (UHDRS-TFC) benefit over placebo in HD.
  target_mechanisms:
  - target: Medium Spiny Neuron Degeneration
    treatment_effect: MODULATES
    description: >-
      Infused dental pulp stem cells are proposed to act through neurotrophic
      support and modulation of neuroinflammation, aiming to protect vulnerable
      striatal medium spiny neurons rather than replace them.
  - target: Neuroinflammation
    treatment_effect: MODULATES
    description: >-
      hDPSCs have immunomodulatory and anti-inflammatory properties hypothesized
      to dampen the neuroinflammatory component of HD striatal degeneration.
- name: Genetic Counseling
  description: >-
    Predictive genetic testing and counseling for at-risk family members. Pre-symptomatic
    testing follows international guidelines (HDSA/IHA/WFN) requiring pre- and post-test
    counseling. Only 5-20% of at-risk individuals choose predictive testing.
    Reproductive options include PGT-M, prenatal testing, and exclusion testing.
  treatment_term:
    preferred_term: Genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
- name: Supportive Care
  description: >-
    Multidisciplinary care including physical therapy (gait training, fall prevention),
    speech therapy (dysarthria and dysphagia management), occupational therapy,
    nutritional support (high-calorie diets, PEG tube in advanced stages), and
    psychiatric management (SSRIs, SNRIs for depression; antipsychotics for psychosis).
  treatment_term:
    preferred_term: Supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
- name: Antipsychotic Medications
  role: Symptomatic
  description: Used for psychiatric symptoms like irritability and agitation.
  evidence:
  - reference: PMID:27534434
    reference_title: "Antipsychotic drugs in Huntington's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: In clinical practice antipsychotics represent the first choice in the management of chorea in the presence of psychiatric symptoms...
    explanation: The literature states that antipsychotics are used to manage psychiatric symptoms in Huntington's Disease.
  - reference: PMID:16383221
    reference_title: "Behavioral symptoms associated with Huntington's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: According to clinical observation, HD patients with psychiatric symptoms respond to standard pharmacotherapy.
    explanation: The literature supports the use of pharmacotherapy, which includes antipsychotic medications, for psychiatric symptoms in Huntington's Disease.
  - reference: PMID:36496108
    reference_title: "Neuropharmacological effect of risperidone: From chemistry to medicine."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Several lines of evidence suggest a possible role of risperidone via the antagonistic effect of Dopamine D2 and 5HT-receptor in different neurological diseases like cognitive dysfunction of schizophrenia, neuroinflammation, Huntington's disease...
    explanation: Risperidone, an antipsychotic, is mentioned as having a role in treating psychiatric symptoms in Huntington's Disease.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
- name: Selective Serotonin Reuptake Inhibitors (SSRIs)
  role: Symptomatic
  description: Used to manage depression.
  evidence:
  - reference: PMID:18394562
    reference_title: "Symptomatic treatment of Huntington disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Several classes of medications have been used to ameliorate the various symptoms of HD, including typical and atypical neuroleptics, dopamine depleters, antidepressants...
    explanation: The abstract mentions that antidepressants, which include SSRIs, are used to manage symptoms in Huntington's Disease.
  - reference: PMID:22119091
    reference_title: "Suicidality in Huntington's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cross-sectionally, suicidal mutation carriers were more likely to use antidepressants (odds ratio=5.3)...
    explanation: The use of antidepressants, which can include SSRIs, is associated with managing depressive symptoms in Huntington's Disease.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
animal_models:
- species: Mouse
  genotype: R6/2 Transgenic
  description: Mice expressing human mutant huntingtin with expanded CAG repeats used to model motor and cognitive deficits.
  associated_phenotypes:
  - Progressive Motor Dysfunction
  - Cognitive Impairment
  - Weight Loss
  evidence:
  - reference: PMID:18638556
    reference_title: "Rodent genetic models of Huntington disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Huntington disease (HD) is a dominantly inherited human neurodegenerative disorder characterized by motor deficits, cognitive impairment, and psychiatric symptoms leading to inexorable decline and death. Since the identification of the huntingtin gene and the characteristic expanded CAG repeat/polyglutamine mutation, multiple murine genetic models and one rat genetic model have been generated.
    explanation: This reference supports the statement as it describes Huntington's disease as involving motor deficits and cognitive impairment, and mentions the use of murine genetic models, including transgenic ones with expanded CAG repeats like the R6/2 model.
  - reference: PMID:35007790
    reference_title: "Hypothalamic expression of huntingtin causes distinct metabolic changes in Huntington's disease mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We used the R6/2 and BACHD mouse models that express different lengths of mutant HTT to develop lean- and obese phenotypes, respectively. We utilized adeno-associated viral vectors to overexpress either mutant or wild-type HTT in the hypothalamus of R6/2, BACHD, and their wild-type littermates. The metabolic phenotype was assessed by body weight measurements over time and body composition analysis using dual-energy x-ray absorptiometry at the endpoint.
    explanation: This reference supports the statement by describing the use of R6/2 mice, which express mutant HTT, to study metabolic phenotypes including weight changes, indicating weight loss as part of the disease phenotype.
  - reference: PMID:29856017
    reference_title: "Motor Assessment in Huntington's Disease Mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Motor deficits are a characteristic consequence of striatal damage, whether induced by experimental lesions, or in genetic models of Huntington's disease involving polyglutamine expansion in the huntingtin protein.
    explanation: This reference supports the statement by confirming that motor deficits are a characteristic consequence of genetic models of Huntington's disease, including those with polyglutamine expansion such as the R6/2 model.
  - reference: PMID:31868674
    reference_title: "Correlations Between Mutant Huntingtin Aggregates and Behavioral Changes in R6/1 Mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: 'Huntington''s disease (HD) is a neurodegenerative disorder caused by the expansion of the trinucleotide CAG in the HD gene. While the presence of nuclear aggregates of mutant huntingtin (mHtt) in neurons is a hallmark of HD, the reason behind its toxicity remains elusive. OBJECTIVE: The present study was conducted to assess a correlation between the number of mHtt aggregates and the severity of HD symptoms in R6/1 mice.'
    explanation: This reference supports the statement by describing the use of R6/1 mice, a similar model to R6/2, to study the correlation between mutant huntingtin aggregates and the severity of HD symptoms, including motor and cognitive deficits.
  - reference: PMID:15525658
    reference_title: "Orexin loss in Huntington's disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We describe for the first time a dramatic atrophy and loss of orexin neurons in the lateral hypothalamus of R6/2 mice. Importantly, we also found a significant atrophy and loss of orexin neurons in Huntington patients.
    explanation: This reference supports the statement by describing the use of R6/2 mice to model Huntington's disease, noting significant neuronal changes that correlate with the disease phenotype.
diagnosis:
- name: Genetic Testing for HTT CAG Expansion
  presence: Positive
  notes: Confirmation of diagnosis through DNA analysis.
  evidence:
  - reference: PMID:26439718
    reference_title: "Huntington Disease: Molecular Diagnostics Approach."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Huntington disease (HD) is caused by expansion of a CAG trinucleotide repeat in the first exon of the Huntingtin (HTT) gene. Molecular testing of Huntington disease for diagnostic confirmation and disease prediction requires detection of the CAG repeat expansion.
    explanation: The literature confirms that genetic testing for HTT CAG expansion is used for the diagnostic confirmation of Huntington's Disease.
  - reference: PMID:23390178
    reference_title: "The challenge of juvenile Huntington disease: to test or not to test."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We analyzed the clinical and genetic characteristics of 76 juvenile-onset patients referred consecutively for HD genetic testing over a 16-year period. ... All expanded cases had a family history of genetically confirmed HD compared to only 13.5% of unexpanded cases (p = 0.000).
    explanation: This study supports the use of genetic testing for confirming the diagnosis of Huntington's Disease by identifying the CAG expansion.
  - reference: PMID:31820322
    reference_title: "Late-onset Huntington's disease with 40-42 CAG expansion."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Huntington's disease (HD) is a rare autosomal dominant neurodegenerative disorder caused by a CAG expansion greater than 35 in the IT-15 gene.
    explanation: This reference supports the statement that Huntington's Disease is confirmed through genetic testing for HTT CAG expansion.
  - reference: PMID:28947110
    reference_title: "Genetic testing for Huntington disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The gene for HD was found in 1993, allowing for direct gene testing for the mutant HTT allele.
    explanation: The discovery of the HD gene allows for direct genetic testing to confirm the presence of HTT CAG expansion, supporting the statement.
- name: Neurological Examination
  notes: Assessment of motor disturbances, cognitive function, and psychiatric symptoms.
  evidence:
  - reference: PMID:29856017
    reference_title: "Motor Assessment in Huntington's Disease Mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Motor deficits are a characteristic consequence of striatal damage, whether induced by experimental lesions, or in genetic models of Huntington's disease involving polyglutamine expansion in the huntingtin protein.
    explanation: This reference supports the assessment of motor disturbances in Huntington's Disease.
  - reference: PMID:29278291
    reference_title: "Rating scales for cognition in Huntington's disease: Critique and recommendations."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Cognitive impairment is one of the main features of Huntington's disease and is present across the disease spectrum.
    explanation: This reference supports the assessment of cognitive function in Huntington's Disease.
  - reference: PMID:30012004
    reference_title: "Huntington's disease: Neuropsychiatric manifestations of Huntington's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: This clinical update review focuses on the common neuropsychiatric manifestations in HD, and outlines and evaluates the various neuropsychiatric facets of HD, including the aetiology, symptoms and diagnosis.
    explanation: This reference supports the assessment of psychiatric symptoms in Huntington's Disease.
  - reference: PMID:31922295
    reference_title: "Early-Motor Phenotype Relates to Neuropsychiatric and Cognitive Disorders in Huntington's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: To determine the relationships between the motor phenotype and the presence of specific neuropsychiatric and neuropsychological disorders in patients with early motor-manifest Huntington's disease.
    explanation: This reference supports the assessment of motor disturbances, cognitive function, and psychiatric symptoms in Huntington's Disease.
  - reference: PMID:36450478
    reference_title: "Impairments to executive function in emerging adults with Huntington disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Recent reports highlight the onset of cognitive and psychiatric symptoms before motor manifestations.
    explanation: This reference supports the assessment of cognitive function and psychiatric symptoms in Huntington's Disease.
clinical_trials:
- name: NCT07451613
  phase: PHASE_I
  status: RECRUITING
  description: >-
    REGEN4HD — the first-in-human Phase 1b/2a study (UCI Health) evaluating the
    safety and tolerability of hNSC-01, GMP-grade human embryonic stem
    cell-derived neural stem cells, stereotactically implanted into the striatum
    of adults with genetically confirmed early-stage Huntington's disease. The
    Phase 1b arm is a dose-escalation cohort followed by a Phase 2a expansion
    group, with treatment-related adverse events as the primary outcome.
  target_phenotypes:
  - preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  - preferred_term: Progressive cognitive decline
    term:
      id: HP:0001268
      label: Mental deterioration
  evidence:
  - reference: clinicaltrials:NCT07451613
    reference_title: "Phase 1B/2A Study of the Safety and Tolerability of Human Neural Stem Cells for Huntington's Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "to determine whether an implantation of hNSC-01 is a safe and tolerable study intervention for Huntington's disease"
    explanation: >-
      ClinicalTrials.gov record for REGEN4HD describes the first-in-human
      evaluation of intrastriatal hNSC-01 neural stem cell therapy for safety
      and tolerability in Huntington's disease.
- name: NCT04120493
  phase: PHASE_I
  status: ACTIVE_NOT_RECRUITING
  description: >-
    First-in-human Phase 1/2, randomized, double-blind, sham-controlled and
    open-label study of striatally-administered rAAV5-miHTT total HTT-lowering
    gene therapy (AMT-130) in early manifest Huntington's disease. The high-dose
    cohort showed slowing of clinical progression and lowered CSF neurofilament
    light chain at 36 months.
  target_phenotypes:
  - preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  - preferred_term: Progressive cognitive decline
    term:
      id: HP:0001268
      label: Mental deterioration
  evidence:
  - reference: clinicaltrials:NCT04120493
    reference_title: "A Phase 1/2, Randomized, Double-Blind, Sham Control and Open-Label Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington's Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC)."
    explanation: >-
      ClinicalTrials.gov record for the first-in-human gene therapy trial of
      AAV5-miHTT (AMT-130) in early manifest Huntington's disease.
- name: NCT03252535
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Phase II, single-center, randomized (2:2:1), triple-blind, placebo-controlled
    dose-response study of intravenous allogeneic human dental pulp stem cells
    (Cellavita HD / NestaCell) in Huntington's disease. Reported a favorable
    safety profile with significant motor and functional improvement over
    placebo, supporting advancement to Phase III.
  target_phenotypes:
  - preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  - preferred_term: Progressive cognitive decline
    term:
      id: HP:0001268
      label: Mental deterioration
  evidence:
  - reference: clinicaltrials:NCT03252535
    reference_title: "Dose-Response Evaluation of the Investigational Product Cellavita HD After Intravenous Administration in Patients With Huntington's Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cellavita HD is a stem-cell therapy for Huntington's Disease."
    explanation: >-
      ClinicalTrials.gov record describing the Phase II dental pulp stem cell
      (Cellavita HD) study in Huntington's disease.
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
discussions:
- discussion_id: gap_hd_somatic_expansion_threshold_rescue
  prompt: >-
    Is somatic HTT CAG expansion past a repeat-length threshold a causal,
    cell-autonomous trigger for medium spiny neuron degeneration, and can
    MSH3/FAN1-pathway modulation shift neurons below that threshold without
    unacceptable DNA-repair toxicity?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Somatic CAG Repeat Expansion
  - pathophysiology#Medium Spiny Neuron Degeneration
  - pathophysiology#Mutant Huntingtin Protein Aggregation
  rationale: >-
    Human single-cell data now argue for a long silent phase of somatic repeat
    growth followed by a high-repeat toxicity threshold. A standardized
    isogenic striatal-neuron experiment would separate repeat-length threshold,
    mutant huntingtin proteostasis, and DNA-repair perturbation effects before
    treating somatic-expansion inhibition as a general disease-modifying
    strategy.
  proposed_experiments:
  - experiment_id: exp_hd_isogenic_spn_repeat_threshold_modulation
    name: Isogenic hPSC striatal-neuron somatic-expansion threshold assay
    description: >-
      Generate isogenic hPSC-derived striatal projection neuron cultures with
      defined HTT CAG lengths; induce or monitor somatic expansion over
      maturation; perturb MSH3 and FAN1 pathway activity; then pair single-cell
      repeat sizing with neuronal identity, stress, survival, and mutant
      huntingtin aggregation readouts.
    experiment_type:
      preferred_term: isogenic stem-cell perturbation experiment
    model_systems:
    - name: Isogenic hPSC-derived striatal projection neuron model
      description: >-
        Human pluripotent-stem-cell-derived striatal neuron system carrying
        controlled HTT CAG tracts so repeat-length distributions can be linked
        to cell-state and degeneration readouts in the same cells.
      experimental_model_type: IPSC_DERIVED_MODEL
      organism:
        preferred_term: human
        term:
          id: NCBITaxon:9606
          label: Homo sapiens
      tissue_term:
        preferred_term: striatum
      cell_types:
      - preferred_term: medium spiny neuron
      cell_source: isogenic hPSC-derived neurons with engineered HTT CAG tracts
      culture_system: long-maturation striatal neuron culture or striatal organoid slice
    perturbations:
    - name: HTT CAG tract length series
      target: pathophysiology#HTT CAG Repeat Expansion
      description: >-
        Isogenic allelic series spanning reduced-penetrance, typical adult-onset,
        and high-repeat HTT CAG lengths.
      gene:
        preferred_term: HTT
        term:
          id: hgnc:4851
          label: HTT
    - name: MSH3 suppression
      target: pathophysiology#Somatic CAG Repeat Expansion
      description: >-
        Genetic or pharmacologic reduction of mismatch-repair activity predicted
        to slow somatic CAG expansion.
      gene:
        preferred_term: MSH3
    - name: FAN1 enhancement
      target: pathophysiology#Somatic CAG Repeat Expansion
      description: >-
        FAN1-pathway enhancement to test whether repeat-stabilizing activity
        can preserve neuronal identity without broad DNA-repair toxicity.
      gene:
        preferred_term: FAN1
    readouts:
    - name: Single-cell HTT CAG repeat-length distribution
      target: pathophysiology#Somatic CAG Repeat Expansion
      description: Repeat length measured in the same cells used for transcriptomic state assignment.
      assays:
      - preferred_term: single-cell repeat-length sequencing
      - preferred_term: long-read sequencing
      direction: POSITIVE
    - name: Medium spiny neuron identity and survival
      target: pathophysiology#Medium Spiny Neuron Degeneration
      description: >-
        Loss of striatal neuron markers, stress-state induction, and cell-loss
        readouts interpreted against CAG threshold crossing.
      assays:
      - preferred_term: single-cell transcriptomic profiling
      - preferred_term: cell viability assay
      direction: POSITIVE
    - name: Mutant huntingtin aggregation burden
      target: pathophysiology#Mutant Huntingtin Protein Aggregation
      description: Aggregation or nuclear-inclusion readout paired to repeat length.
      assays:
      - preferred_term: immunofluorescence assay
      direction: POSITIVE
    controls:
    - name: Isogenic non-expanded HTT neurons
      description: Matched striatal neurons carrying nonpathogenic HTT CAG length.
    - name: Sham-edited expanded HTT neurons
      description: Expanded-CAG neurons receiving editing or delivery controls only.
    decision_criterion: >-
      The threshold model is supported if neurons crossing a prespecified high
      somatic-repeat range lose striatal identity and viability, and if MSH3
      suppression or FAN1 enhancement reduces both threshold crossing and
      degeneration without broad DNA-damage readouts.
    would_support:
    - pathophysiology#Somatic CAG Repeat Expansion
    - pathophysiology#Medium Spiny Neuron Degeneration
    would_refute:
    - pathophysiology#Somatic CAG Repeat Expansion
    evidence:
    - reference: PMID:39824182
      reference_title: "Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Somatic expansion from 40 to 150 CAGs had no apparent cell-autonomous effect"
      explanation: >-
        Establishes the threshold-like causal question by separating lower
        somatic expansion from the larger expansions linked to neuronal collapse.
    - reference: PMID:39824182
      reference_title: "Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "somatic repeat expansion beyond 150 CAGs causes SPNs to degenerate quickly and asynchronously"
      explanation: >-
        Supports testing whether repeat-stabilizing perturbations can prevent
        the high-repeat state in a controlled human neuronal model.
    - reference: PMID:33579859
      reference_title: "Genetic modifiers of Huntington disease differentially influence motor and cognitive domains."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Validation of leads including the mismatch repair protein MSH3, and
        interstrand cross-link repair protein FAN1, suggest the mechanism is driven
        by somatic CAG instability
      explanation: >-
        Provides the genetic-modifier rationale for MSH3 and FAN1 perturbations.
datasets:

📚

References & Deep Research

Deep Research

1

OpenScientist ▸

Huntington Disease: Comprehensive Disease Characteristics Report

openscientist-autonomous 25 citations 2026-04-07T09:05:30.235049

Huntington Disease: Comprehensive Disease Characteristics Report

Executive Summary

Huntington Disease (HD) is a devastating, autosomal dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion (≥36 repeats; full penetrance ≥40) in exon 1 of the huntingtin gene (HTT) on chromosome 4p16.3. The expanded polyglutamine tract in the huntingtin protein — a 3,144 amino acid multifunctional scaffold essential for vesicular transport, transcription, autophagy, and neuronal survival — causes misfolding, aggregation, and toxic gain-of-function, preferentially destroying GABAergic medium spiny neurons (MSNs) in the striatum through eight converging pathogenic mechanisms. HD manifests as a clinical triad of progressive motor dysfunction (chorea evolving to rigidity), cognitive decline progressing to dementia, and psychiatric disturbances, with detectable premanifest changes beginning 15-20 years before motor onset. With a prevalence of approximately 5-7 per 100,000 in Western populations (~30,000 affected in the US), HD remains without disease-modifying therapy, though three VMAT2 inhibitors provide symptomatic chorea relief. The therapeutic landscape is undergoing a paradigm shift following the tominersen trial failure, with the most promising emerging strategies being somatic CAG expansion inhibitors (targeting MSH3/FAN1), allele-selective HTT lowering, and AAV-mediated gene therapy, supported by HD's uniquely organized global research infrastructure.

This report covers 21 sections: genetics, disease identifiers, epidemiology, huntingtin protein biology, molecular pathogenesis, neuropathology, clinical features, premanifest phase, differential diagnosis, diagnosis, current treatment, therapeutic pipeline, animal models, emerging concepts, genetic counseling, psychosocial impact, intermediate alleles, treatment comparison, clinical trial lessons, research infrastructure, and future directions.

1. Genetic Basis

1.1 The HTT Gene and CAG Repeat Expansion

Gene: HTT (Huntingtin), located on chromosome 4p16.3
Mutation: Expansion of a polymorphic CAG trinucleotide repeat in exon 1
Protein product: Huntingtin (HTT), a large ~348 kDa scaffolding protein with roles in vesicular transport, transcriptional regulation, and cell survival
Inheritance: Autosomal dominant with complete penetrance at ≥40 CAG repeats

1.2 CAG Repeat Length Categories

Category	CAG Length	Clinical Significance
Normal	6–26	No risk of HD; stable across generations
Intermediate (mutable normal)	27–35	No HD risk, but may expand in offspring (especially paternal transmission)
Reduced penetrance	36–39	Some individuals develop HD; incomplete penetrance
Full penetrance	≥40	Will develop HD if normal lifespan
Juvenile onset	≥60	Onset typically before age 20; more rigid/akinetic phenotype

1.3 CAG Length and Age of Onset

The CAG repeat length is inversely correlated with age of motor onset and accounts for approximately 50–70% of the variance in onset age. However, the remaining variance is influenced by:

Genetic modifiers: DNA mismatch repair genes (MSH3, FAN1, MLH1, PMS1, PMS2, LIG1)
Somatic CAG expansion: Progressive lengthening of the CAG repeat in somatic cells, particularly in striatal neurons
Environmental factors: Exercise, cognitive reserve, and other lifestyle factors (less well-characterized)

1.4 Anticipation

HD shows genetic anticipation, particularly with paternal transmission. The CAG repeat is unstable during spermatogenesis, leading to potential intergenerational expansions. This explains why juvenile HD cases are more commonly paternally inherited.

2. Disease Identifiers

Database	Identifier
OMIM	143100
MONDO	MONDO:0007739
Orphanet	ORPHA:399
MeSH	D006816
ICD-10	G10
DOID	DOID:12858

3. Epidemiology

3.1 Prevalence

Population	Prevalence per 100,000
North America (Caucasian)	~7.33
Western Europe	~5.70
Australia	~5.63
Finland	~2.12
South America	~1.57
Japan	~0.72
East Asia	~0.40
Sub-Saharan Africa	~0.02

Global estimate: ~2.7 per 100,000 overall
United States: ~30,000 affected individuals; ~200,000 at risk
Trend: Prevalence appears to be increasing in Western countries due to improved diagnosis, genetic testing, longer survival with supportive care, and new mutations from intermediate alleles

3.2 Incidence

Approximately 0.4–0.5 per 100,000 per year in Western populations
Higher in populations with European ancestry

3.3 Population Variation

The marked ethnic/geographic variation in prevalence correlates with the distribution of intermediate and high-normal CAG alleles. Western European populations have a higher proportion of alleles near the pathogenic threshold, providing a reservoir for new mutations through intergenerational expansion.

4. Huntingtin Protein Biology

4.1 Protein Structure

Huntingtin is a large (3,144 amino acids, ~348 kDa) scaffold protein containing: - Polyglutamine (polyQ) tract: Encoded by the CAG repeat in exon 1; normally 6-26 Qs - Proline-rich domain (PRD): Adjacent to polyQ; modulates aggregation propensity - HEAT repeats: Four clusters of α-helical repeat domains forming a solenoid structure; mediate protein-protein interactions - Subcellular localization: Nucleus, cytoplasm, axons, dendrites, perikaryon, and associated with vesicles and organelles

4.2 Normal Functions of Wild-Type Huntingtin

Function	Mechanism	Relevance to HD
Vesicular transport	Scaffold for dynein/kinesin motors on microtubules	mHTT impairs BDNF transport cortex→striatum
Transcription regulation	Interacts with REST/NRSF, CBP, Sp1, TFIID	mHTT sequesters transcription factors → gene silencing
Autophagy	Scaffold for autophagy initiation and cargo recognition	mHTT aggregates overwhelm and impair autophagy
Anti-apoptotic signaling	Sequesters caspase-3; blocks pro-apoptotic HIP-1	Loss of function removes survival signaling
Embryonic development	Essential for gastrulation	HTT knockout is embryonic lethal (E7.5)
Synaptic function	Vesicle recycling and neurotransmitter release	Synaptic dysfunction is an early HD feature

4.3 Key Post-Translational Modifications

Modification	Site	Function	HD Relevance
Phosphorylation	S421 (Akt/SGK)	Neuroprotective; promotes BDNF transport	Lowest in striatum → vulnerability factor (PMID: 18992820)
Phosphorylation	S13/S16	Regulates mHTT clearance	Phospho-mimetic reduces toxicity
Acetylation	K444	Promotes autophagic clearance	Impaired acetylation → mHTT accumulation
Caspase cleavage	D513, D552, D586	Generates N-terminal fragments	Fragments with expanded polyQ are highly toxic
Palmitoylation	C214 (HIP14-mediated)	Membrane targeting/trafficking	Reduced in HD → altered protein trafficking
SUMOylation	K6, K9, K15	Competes with ubiquitination	Alters aggregation and clearance dynamics

Key Insight: The finding that S421 phosphorylation is naturally lowest in striatal neurons provides a molecular explanation for selective vulnerability — these neurons have the least protective modification of HTT, making them most susceptible to mHTT toxicity.

4.4 Signaling Pathways Involving HTT

Wikidata pathway analysis reveals HTT participates in multiple critical signaling cascades: MAPK, Wnt, insulin, TGF-beta, VEGF, apoptosis, PDGF, p38 MAPK, ErbB, toll-like receptor, and inflammatory (IL-1, IL-6, TNF-alpha) pathways. This broad involvement explains why mHTT disruption has such pleiotropic effects.

5. Molecular Pathogenesis

5.1 Mutant Huntingtin Protein (mHTT) Toxicity

The expanded polyglutamine (polyQ) tract causes huntingtin to: 1. Misfold and aggregate → forms intranuclear inclusions and cytoplasmic aggregates 2. Sequester essential proteins → disrupts proteostasis, transcription, and transport 3. Undergo aberrant proteolytic cleavage → generates toxic N-terminal fragments

5.2 Key Pathogenic Mechanisms

Protein aggregation and proteostasis failure: mHTT overwhelms the ubiquitin-proteasome system and autophagy pathways
Transcriptional dysregulation: mHTT interacts with and sequesters transcription factors (CBP, Sp1, TFIID, REST/NRSF), leading to widespread gene expression changes, including downregulation of BDNF and PGC-1α
Mitochondrial dysfunction: Impaired Complex II/III activity, reduced ATP production, increased oxidative stress, defective mitochondrial dynamics (fission/fusion)
Excitotoxicity: Enhanced sensitivity of MSNs to glutamate via NMDA receptors, leading to calcium overload and cell death
BDNF depletion: mHTT impairs BDNF transcription in cortical neurons and disrupts vesicular transport of BDNF along the corticostriatal pathway
Somatic CAG repeat expansion: DNA mismatch repair (MMR) machinery drives progressive lengthening of the CAG repeat in post-mitotic neurons, particularly in the striatum; this is now recognized as a critical determinant of disease onset
Synaptic dysfunction: Altered neurotransmitter release, impaired synaptic plasticity, and progressive corticostriatal circuit disruption
Neuroinflammation: Microglial activation, reactive astrocytosis, and elevated inflammatory cytokines (IL-6, IL-8, TNF-α) in both CNS and periphery

5.3 Selective Neuronal Vulnerability

Medium spiny neurons (MSNs) in the caudate nucleus and putamen are preferentially affected due to: - High excitatory glutamatergic input from cortex - Dependence on BDNF from cortical projections - High metabolic demand and vulnerability to energy deficits - Greater somatic CAG expansion in striatal vs. other brain regions - Expression pattern of DNA repair enzymes promoting instability

The indirect pathway MSNs (D2 receptor-expressing, enkephalin-positive) are affected earliest, followed by direct pathway MSNs (D1 receptor-expressing, substance P-positive), correlating with the clinical progression from chorea to rigidity.

6. Neuropathology

6.1 Vonsattel Grading System

Grade	Pathological Features
Grade 0	No gross atrophy; microscopic neuronal loss in caudate head
Grade 1	Mild caudate atrophy; up to 50% neuronal loss in caudate
Grade 2	Moderate caudate atrophy; striatal atrophy visible grossly
Grade 3	Severe striatal atrophy; marked neuronal loss with astrogliosis
Grade 4	Very severe atrophy; >95% neuronal loss in caudate; cortical atrophy

6.2 Brain Regions Affected (in order of severity)

Caudate nucleus (earliest and most severe)
Putamen
Globus pallidus
Cerebral cortex (layers III, V, VI)
Thalamus, subthalamic nucleus
Hippocampus, cerebellum (later stages)

7. Clinical Features

7.1 The Clinical Triad

Motor Symptoms

Chorea (most characteristic): Involuntary, irregular, non-repetitive movements
Dystonia: Sustained abnormal postures, increases as disease progresses
Bradykinesia/rigidity: Increasingly prominent in later stages
Gait disturbance: Wide-based, unsteady gait; falls are common
Oculomotor abnormalities: Saccade initiation difficulties (often earliest motor sign)
Dysphagia: Swallowing difficulty; aspiration pneumonia is a leading cause of death
Dysarthria: Progressive speech deterioration

Cognitive Symptoms

Executive dysfunction: Impaired planning, mental flexibility, multitasking (earliest cognitive change)
Psychomotor slowing: Reduced processing speed
Visuospatial deficits
Memory impairment: Primarily retrieval-based (vs. encoding-based in Alzheimer's)
Progressive dementia: Inevitable in later stages; subcortical pattern
Cognitive changes may precede motor onset by 10-15 years

Psychiatric Symptoms (often precede motor onset)

Depression: 33–69% of patients; suicide risk elevated 5-10x
Irritability/aggression: Common and distressing for families
Anxiety: 34–61% of patients
Apathy: Increases with disease progression; distinct from depression
Obsessive-compulsive behaviors: 10–52%
Psychosis: Relatively rare (<10%)
Disinhibition and impulsivity

7.2 Other Clinical Features

Weight loss: Progressive, multifactorial (increased energy expenditure, dysphagia, hypothalamic dysfunction)
Sleep disturbances: Circadian rhythm disruption, insomnia, increased sleep latency (prevalence systematically studied; PMID: 41722529)
Autonomic dysfunction: Bowel/bladder issues
Peripheral manifestations: Skeletal muscle wasting, cardiac dysfunction, immune dysregulation

7.3 Disease Stages (Shoulson-Fahn Total Functional Capacity)

Stage	TFC Score	Duration	Key Features
I	11–13	~8 years	Subtle motor/cognitive changes; fully functional
II	7–10	~3 years	Chorea more evident; reduced work capacity
III	3–6	~3 years	Cannot work; needs assistance with finances
IV	1–2	~3 years	Requires substantial assistance with daily living
V	0	Variable	Total dependence; nursing care required

Mean age of motor onset: ~45 years (range: childhood to >70 years) Mean disease duration: 15–20 years from motor onset to death Cause of death: Most commonly aspiration pneumonia, followed by cardiovascular disease and suicide

7.4 Juvenile Huntington Disease (JHD)

Onset before age 20 (approximately 5-10% of cases)
More commonly paternally inherited (CAG expansion during spermatogenesis)
Phenotype differs from adult-onset: rigidity and bradykinesia predominate (vs. chorea)
Additional features: seizures (25-40%), rapid cognitive decline, cerebellar ataxia
Faster progression; mean duration ~8-10 years

8. The Premanifest Phase: A Window for Intervention

HD is unique among neurodegenerative diseases in that gene-positive individuals can be identified decades before clinical onset, enabling detailed characterization of the premanifest phase.

8.1 Timeline of Premanifest Changes

Years Before Motor Onset	Change Detectable
~20 years	Plasma NfL begins to rise above controls
~15-20 years	Subtle striatal (caudate) atrophy on volumetric MRI
~10-15 years	Executive dysfunction and processing speed deficits detectable on neuropsychological testing
~5-10 years	Psychiatric symptoms (depression, irritability, anxiety) may appear
~2-5 years	Subtle motor signs (oculomotor abnormalities, finger tapping irregularities)
0 years	Clinical motor diagnosis (UHDRS Diagnostic Confidence Level 4)

8.2 Key Observational Studies

PREDICT-HD: Demonstrated that cognitive and brain imaging changes are detectable up to 15+ years before motor diagnosis
TRACK-HD/TRACK-ON: Longitudinal study showing progressive striatal atrophy, white matter changes, and cognitive decline in premanifest carriers
ENROLL-HD: World's largest observational study of HD families (>20,000 participants); provides natural history data and machine-learning progression models (PMID: 34870344)

8.3 Therapeutic Implications

The extended premanifest phase, combined with genetic predictability and measurable biomarkers (NfL, volumetric MRI), makes HD uniquely suited for preventive clinical trials. Intervening before irreversible neuronal loss could maximize therapeutic benefit. Current trials (e.g., HD-DCI) are enrolling premanifest carriers based on biomarker-predicted proximity to onset.

9. Differential Diagnosis

9.1 Genetic HD Phenocopies (HTT-Negative)

Approximately 2-40% of patients presenting with an HD-like phenotype test negative for HTT CAG expansion (PMID: 41612618). Key phenocopies include:

Condition	Gene/Mutation	Inheritance	Distinguishing Features
HDL1	PRNP octapeptide repeat insertion	AD	Personality changes, seizures; prion disease
HDL2	JPH3 CTG/CAG expansion	AD	Virtually indistinguishable from HD; common in African ancestry
SCA17	TBP CAG expansion	AD	Prominent ataxia alongside chorea and dementia
C9orf72	GGGGCC repeat expansion	AD	FTD/ALS spectrum features; increasingly recognized HD phenocopy
Chorea-acanthocytosis	VPS13A mutations	AR	Lip/tongue biting, acanthocytes on blood smear
McLeod syndrome	XK gene mutations	X-linked	Acanthocytes, cardiomyopathy, elevated CK
DRPLA	ATN1 CAG expansion	AD	Epilepsy, ataxia; more common in Japan
Benign hereditary chorea	NKX2-1 (TITF1) mutations	AD	Non-progressive; thyroid/lung involvement

9.2 Acquired Causes of Chorea

Condition	Key Diagnostic Features
Sydenham chorea	Post-streptococcal; children; anti-basal ganglia antibodies
SLE/antiphospholipid syndrome	Young women; anti-phospholipid antibodies
Tardive dyskinesia	History of dopamine receptor blocker exposure
Wilson disease	Kayser-Fleischer rings; low ceruloplasmin; liver disease
Anti-NMDAR encephalitis	Young women; psychiatric onset; ovarian teratoma
Polycythemia vera	Elderly; elevated hematocrit
Thyrotoxicosis	Thyroid function abnormalities; reversible

9.3 Diagnostic Algorithm

For patients presenting with chorea ± cognitive/psychiatric features: 1. First-line: HTT CAG repeat testing (definitive for HD) 2. If HTT-negative: Blood smear (acanthocytes), ceruloplasmin/copper (Wilson), thyroid function, ANA/antiphospholipid antibodies 3. If still undiagnosed: Gene panel for HD phenocopies (JPH3, TBP, ATN1, C9orf72, PRNP, VPS13A, XK, NKX2-1) 4. Consider: Brain MRI (caudate atrophy pattern), anti-neuronal antibodies

10. Diagnosis

10.1 Clinical Diagnosis

Based on unequivocal motor signs (chorea or other movement disorder) in the setting of a positive family history
Unified Huntington Disease Rating Scale (UHDRS) for standardized assessment
Diagnostic Confidence Level (DCL) of 4 = motor abnormalities unequivocal and characteristic of HD

10.2 Genetic Testing

Diagnostic testing: PCR-based CAG repeat sizing from blood DNA; ≥36 CAGs confirms genetic diagnosis
Predictive testing: Available for at-risk individuals (50% risk if one parent affected); requires genetic counseling per international guidelines
Prenatal testing: Available via chorionic villus sampling or amniocentesis
Preimplantation genetic testing (PGT): Option for IVF to select unaffected embryos

10.3 Neuroimaging

MRI: Caudate nucleus atrophy (progressive loss of caudate head convexity); measurable years before motor onset
Volumetric MRI: Quantitative striatal volume loss is a sensitive progression biomarker
PET/SPECT: Reduced D2 receptor binding in striatum; reduced glucose metabolism
MR spectroscopy: Altered metabolite profiles (reduced NAA, elevated myo-inositol) in striatum

10.4 Fluid Biomarkers

Biomarker	Specimen	Clinical Utility
Mutant huntingtin (mHTT)	CSF	Pharmacodynamic marker for HTT-lowering therapies
Neurofilament light (NfL)	Plasma/CSF	Neurodegeneration marker; elevated in premanifest HD; tracks progression
GFAP	Plasma/CSF	Not a reliable early marker (PMID: 39891767)
Inflammatory cytokines	Plasma	IL-6, IL-8, TNF-α elevated; correlate with disease burden

11. Current Treatment

11.1 Approved Symptomatic Therapies

Drug	Mechanism	Indication	Year Approved
Tetrabenazine (Xenazine)	VMAT2 inhibitor	Chorea	2008 (FDA)
Deutetrabenazine (Austedo)	Deuterated VMAT2 inhibitor	Chorea	2017 (FDA)
Valbenazine (Ingrezza)	Selective VMAT2 inhibitor	Chorea	2023 (FDA)

11.2 Off-Label and Supportive Treatments

Antipsychotics (olanzapine, risperidone): For chorea, psychosis, aggression
Antidepressants (SSRIs, SNRIs): For depression and anxiety
Benzodiazepines: For anxiety and myoclonus
Physical therapy: Gait training, fall prevention, exercise programs
Speech therapy: For dysarthria and dysphagia management
Occupational therapy: Adaptive strategies for daily living
Nutritional support: High-calorie diets; PEG tube in advanced stages
Palliative care: Increasingly important in advanced disease

11.3 No Disease-Modifying Therapy Is Currently Approved

12. Therapeutic Pipeline and Emerging Strategies

12.1 HTT-Lowering Approaches

Therapy	Type	Status	Notes
Tominersen	Non-selective ASO (intrathecal)	Phase III halted (2021)	Higher doses worsened outcomes; dose-dependent toxicity concerns
WVE-003	Allele-selective ASO (SNP-targeting)	Phase I/II	Targets mHTT-linked SNP; spares wild-type HTT
AMT-130	AAV5-delivered miRNA	Phase I/II	uniQure; one-time striatal injection; targets both HTT alleles
PTC518	Oral splice modulator	Phase II	Promotes HTT exon skipping; oral bioavailability

12.2 Somatic Expansion Inhibitors (Novel Paradigm)

Target: MSH3 (MutSβ complex) — the DNA mismatch repair component that drives somatic CAG expansion
Rationale: GWAS modifier studies show MSH3 variants alter onset age; reducing MSH3 could slow somatic expansion
Status: Multiple preclinical programs; considered the most promising emerging therapeutic approach
FAN1 activation: FAN1 nuclease protects against somatic expansion; activation strategies in development

12.3 Other Approaches

CRISPR gene editing: Direct correction of expanded CAG repeats (preclinical)
Immunotherapy: Targeting extracellular mHTT aggregates
Neuroprotection: BDNF supplementation, mitochondrial enhancers (CoQ10 trials negative)
Cell replacement therapy: iPSC-derived MSN transplantation (very early stage)

13. Animal Models

Model	Type	CAG Length	Key Features
R6/2	Transgenic (exon 1 fragment)	~150	Rapid progression; 12-16 week lifespan; robust phenotype
R6/1	Transgenic (exon 1 fragment)	~115	Slower progression than R6/2
YAC128	Transgenic (full-length)	128	Full-length mHTT; striatal-specific neurodegeneration
BACHD	Transgenic (BAC, full-length)	97	Metabolic phenotype; slower progression
zQ175	Knock-in	~175	Somatic expansion; closest to human genetics
HdhQ111	Knock-in	111	Endogenous promoter; somatic instability
OVT73 sheep	Transgenic	73	Large animal model; closer to human brain size
HD minipig	Knock-in	~124	Large animal; long lifespan for longitudinal studies

14. Key Emerging Concepts

14.1 HD as a Developmental Disorder

Recent evidence suggests mHTT affects brain development, with subtle abnormalities in cortical and striatal organization present from early life, years before clinical onset (PMID: 41252373). This challenges the traditional view of HD as purely a late-onset neurodegenerative disease.

14.2 Somatic Instability as the Central Disease Driver

The recognition that somatic CAG expansion in striatal neurons may be the rate-limiting step in disease onset has fundamentally shifted the therapeutic paradigm. The inherited CAG length sets the stage, but it is the ongoing somatic expansion that ultimately triggers neuronal death.

14.3 Peripheral Pathology

HD is increasingly recognized as a systemic disease, with pathology in skeletal muscle, heart, immune system, and endocrine organs, challenging the CNS-centric view.

14.4 Biomarker-Driven Clinical Trials

NfL in plasma has emerged as a powerful, minimally invasive biomarker that can detect disease-related changes in premanifest HD carriers and may serve as a surrogate endpoint in clinical trials.

15. Genetic Counseling and Predictive Testing

15.1 Predictive Testing Framework

Eligibility: At-risk individuals (typically ≥18 years) with a first-degree relative with confirmed HD
Uptake: Only ~5-20% of at-risk individuals choose predictive testing
International guidelines (HDSA/IHA/WFN) require pre- and post-test genetic counseling
Protocol: Minimum two counseling sessions; psychological assessment; neurological exam; waiting period between sessions; post-result follow-up
"Right not to know": Must be respected; testing of minors is generally discouraged unless medically indicated

15.2 Reproductive Options

Option	Description	Considerations
Natural conception	Accept 50% risk	Informed choice with genetic counseling
Prenatal testing	CVS at 10-12 wks or amniocentesis at 15-18 wks	Requires decision about potential termination
Exclusion testing	Tests linkage without revealing parent's status	Preserves parental autonomy; complex
PGT-M (PGD)	IVF with embryo selection	Avoids termination; costly; not universally available
Gamete donation	Donor egg/sperm from non-carrier	Eliminates genetic risk entirely
Adoption	Non-biological parenting	No genetic risk; availability varies

15.3 Ethical and Legal Considerations

Genetic Information Nondiscrimination Act (GINA, US): Protects against discrimination in health insurance and employment based on genetic information, but does NOT cover life, disability, or long-term care insurance
Duty to warn: Genetic counselors face ethical tensions between patient confidentiality and potential duty to inform at-risk relatives
Incidental findings: Expanded testing panels may reveal HD risk incidentally
Psychological impact of results: Both positive AND negative results can cause psychological distress (survivor guilt, altered family dynamics)

16. Psychosocial Impact and Family Burden

16.1 Impact on Patients

Suicide: Risk 5-10x general population; highest around time of diagnosis and in early-mid stages when awareness is preserved
Depression: Affects 33-69% of patients; both reactive and neurobiological components
Employment: Progressive inability to work; mean retirement ~5-8 years after motor onset
Driving cessation: Usually required within first few years of motor onset
Decision-making capacity: Progressively impaired; advance care planning essential early

16.2 Impact on Families and Caregivers

Caregiver burden: Averages 40-70 hours/week in advanced stages (PMID: 26688844)
Multi-generational impact: Children witness parent's decline while potentially carrying the gene
Relationship strain: Behavioral changes (apathy, irritability, disinhibition) challenge partnerships
Financial impact: Estimated $50,000-$100,000+/year in advanced stages (US); loss of income compounds costs
Caregiver health: Elevated rates of depression, anxiety, and physical health problems

16.3 Support Resources

Huntington's Disease Society of America (HDSA): Centers of Excellence, support groups, social services
European Huntington's Disease Network (EHDN): Research and care coordination
HD Youth Organization (HDYO): Resources specifically for young people impacted by HD
ENROLL-HD: Global observational study providing community and research connection

17. Intermediate Alleles and New Mutations

17.1 Population Genetics of Intermediate Alleles

~2-7% of the general population carries intermediate alleles (27-35 CAGs)
Prevalence varies by ethnicity, highest in Western European populations
Meiotically unstable, especially during spermatogenesis (paternal transmission)
~6-10% chance of expansion into disease range per paternal transmission
Alleles at 33-35 CAGs carry the highest expansion risk

17.2 Clinical Significance

Intermediate allele carriers themselves do NOT develop HD
However, a scoping review (PMID: 41406155) found some evidence of subtle phenotypic features in carriers:
Possible mild cognitive or psychiatric symptoms
Subtle motor signs in some individuals
Clinical significance remains debated; most carriers are fully asymptomatic
Accounts for ~1-3% of HD cases presenting without family history ("sporadic" or "de novo" HD)

17.3 Evolutionary Implications

Intermediate alleles represent a mutation-selection balance: new mutations continuously arise from the intermediate allele pool, maintaining HD in the population despite the reduced reproductive fitness of affected individuals. This also explains why HD prevalence is higher in populations (Western European) with larger proportions of high-normal/intermediate alleles.

18. VMAT2 Inhibitor Treatment Comparison

Based on a Bayesian network meta-analysis (PMID: 41069601):

Feature	Tetrabenazine	Deutetrabenazine	Valbenazine
FDA Approval	2008	2017	2023
Dosing	TID (3x/day)	BID (2x/day)	QD (1x/day)
CYP2D6 metabolism	Significant interaction	Reduced	Minimal
Chorea reduction (UHDRS-TMS)	~5 points	~4.4 points	~3.2 points
Sedation/fatigue	Common (>30%)	Less common	Less common
Depression risk	Boxed warning	Lower risk	Lower risk
Key advantage	Most clinical experience	Better tolerability	Once daily; sprinkle formulation
Formulations	Tablets	Tablets	Capsules + sprinkle (PMID: 41215526)

Clinical Pearl: All three VMAT2 inhibitors are symptomatic only (reduce chorea severity); none modify disease progression. Treatment choice should be individualized based on patient comorbidities, polypharmacy, and tolerance.

19. Lessons from Clinical Trials

19.1 The Tominersen Pivotal Moment

The Phase III GENERATION-HD1 trial of tominersen (Roche/Ionis) — a non-selective antisense oligonucleotide targeting both mutant and wild-type HTT via intrathecal delivery — was halted in March 2021 after an independent monitoring committee found that higher doses worsened clinical outcomes compared to placebo. Key lessons:

Non-selective HTT lowering is risky: Wild-type HTT has essential functions; reducing it below a critical threshold may cause harm
Neuroinflammation from intrathecal delivery: The procedure and drug itself may trigger CNS inflammation independent of target engagement
Dose-response is not linear: Higher doses ≠ better outcomes; there may be a narrow therapeutic window
Patient stratification matters: Younger patients with lower disease burden may respond differently than advanced patients
Biomarker dissociation: mHTT lowering in CSF did not translate to clinical benefit, questioning CSF mHTT as a surrogate endpoint

19.2 Reshaping the Therapeutic Paradigm

Post-tominersen, the field has shifted toward: - Allele-selective ASOs (WVE-003): Target mHTT-linked SNPs to lower only mutant HTT, preserving wild-type function - One-time gene therapy (AMT-130): AAV-delivered miRNA for sustained local HTT lowering in the striatum - Oral small molecules (PTC518): Splice modulators offering non-invasive, titratable dosing - Somatic expansion inhibitors: An entirely different approach that doesn't require HTT protein lowering — targets the upstream DNA instability mechanism - Combination strategies: Multiple complementary mechanisms may ultimately be needed

19.3 Clinical Trial Design Evolution

Composite endpoints (combining motor, cognitive, and functional measures) now preferred over single-domain endpoints
Enrichment designs using biomarker-defined populations (e.g., NfL-stratified)
Longer trial durations to capture disease-modifying effects vs. symptomatic changes
Adaptive platform designs allowing multiple therapies to be tested simultaneously
Digital and remote assessments to reduce patient burden and increase data granularity

20. Research Infrastructure and Community

20.1 Major Research Platforms

Platform	Description	Scale
ENROLL-HD	Global observational study; natural history data	>20,000 participants, 20+ countries
HDSA Centers of Excellence	Specialized multidisciplinary HD clinics	50+ centers in the US
EHDN	European HD clinical research network	Pan-European coordination
CHDI Foundation	Private foundation dedicated to HD drug discovery	>$100M/year funding
HD Clarity	Multi-site CSF biomarker collection	Global CSF repository
HDClarity	Biofluid collection for biomarker research	Standardized protocols
HDYO	HD Youth Organization	Youth-specific resources and support

20.2 Why HD is Uniquely Positioned for Breakthroughs

HD occupies a uniquely favorable position among neurodegenerative diseases for therapeutic development:

Genetic clarity: Single-gene cause with 100% penetrance at ≥40 CAGs — no diagnostic ambiguity
Predictable trajectory: CAG-based onset prediction enables premanifest intervention
Measurable biomarkers: NfL, mHTT, volumetric MRI provide quantitative tracking
Organized community: Global patient registries, advocacy organizations, and research networks
Paradigm disease: Insights benefit all 45+ trinucleotide repeat disorders and neurodegeneration broadly
Animal models: Well-characterized transgenic and knock-in models spanning mice to large animals

21. Limitations and Future Directions

21.1 Limitations of This Report

Prevalence estimates vary across studies and meta-analyses; some regional data may be outdated
The therapeutic pipeline is rapidly evolving; clinical trial statuses change frequently
Mechanistic understanding continues to evolve, particularly regarding the relative contributions of gain-of-function vs. loss-of-function
Psychosocial burden estimates are based primarily on Western healthcare systems
This report relies on published literature and database queries; unpublished clinical trial data may alter some conclusions

21.2 Key Unanswered Questions

Why are striatal MSNs selectively vulnerable despite ubiquitous HTT expression? (Partial answers: S421-P levels, somatic expansion rates, BDNF dependence — but full picture remains unclear)
What somatic CAG expansion threshold triggers neuronal death? This critical question could define therapeutic targets
Can allele-selective HTT lowering avoid tominersen's toxicity while preserving efficacy?
Is there an optimal therapeutic window in the premanifest phase for disease modification?
What is the contribution of wild-type HTT loss-of-function to HD pathogenesis?
Can somatic expansion be therapeutically stopped or reversed in already-expanded neurons?
Do peripheral manifestations (muscle, heart, immune) require separate therapeutic attention?
Can digital biomarkers provide more sensitive and continuous outcome measures than current clinical scales?

21.3 Future Directions

Direction	Timeline	Potential Impact
Somatic expansion inhibitors (MSH3)	2-5 years to clinical trials	Transformative — addresses root cause
Allele-selective ASOs	3-5 years (Phase II/III data)	High — preserves wild-type HTT
Gene therapy (AAV)	3-7 years (Phase II/III)	High — one-time treatment potential
Combination therapies	5-10 years	Highest — multi-mechanism targeting
Precision medicine	5-10 years	Moderate — CAG + modifier genotyping
Digital biomarkers	1-3 years (adoption)	Moderate — continuous monitoring
Cell replacement therapy	10+ years	Uncertain — circuit replacement challenge
Prevention trials in premanifest carriers	5-10 years	Very high — prevent neurodegeneration

References (Selected Key Publications)

Genetics & Pathogenesis

Donaldson et al. (2026) "Huntington disease: somatic expansion, pathobiology and therapeutics." PMID: 41233526
Shin & Hefti (2025) "Huntington's as a developmental disorder." PMID: 41252373
Maiuri et al. (2021) "DNA Repair in HD: Somatic Instability and Alternative Hypotheses." PMID: 33579859
Warby et al. (2009) "Phosphorylation of huntingtin reduces accumulation of nuclear fragments." PMID: 18992820
Ehrnhoefer et al. (2011) "Posttranslational modifications and function of huntingtin." PMID: 21311053

Biomarkers & Natural History

Paulsen et al. (2025) "Systematic Review with Meta-Analysis of Biofluid Markers for HD." PMID: 41081429
Heim et al. (2025) "Serum NfL but not GFAP is a marker of early HD." PMID: 39891767
Rodrigues et al. (2020) "Mutant huntingtin and NfL have distinct longitudinal dynamics." PMID: 33328328
Wild et al. (2015) "Quantification of mHTT in CSF from HD patients." PMID: 25844897
Mohan et al. (2022) "Machine-Learning Derived HD Progression Model." PMID: 34870344

Therapeutics & Clinical Trials

Saade & Mestre (2024) "HD: Latest Frontiers in Therapeutics." PMID: 38861215
Winquist & Church (2025) "Inhibiting CAG repeat expansions as therapeutic strategy." PMID: 41130308
Huang et al. (2025) "VMAT2 inhibitors for HD chorea: network meta-analysis." PMID: 41069601
Giri et al. (2025) "Valbenazine Sprinkle formulation for dysphagia." PMID: 41215526
Rodrigues et al. (2025) "Cholinesterase inhibitors and memantine for HD cognition." PMID: 40791064

Clinical Features & Phenocopies

van Hofslot et al. (2026) "Clinical phenotype of intermediate allele carriers." PMID: 41406155
Cardoso et al. (2026) "Non-Huntington's disease chorea: expanding universe." PMID: 41612618
Schneider & Bird (2016) "HD, HD Look-Alikes, and Benign Hereditary Chorea." PMID: 30713928
Sneddon et al. (2026) "Sleep disturbances in HD and premanifest carriers." PMID: 41722529

Psychosocial & Epidemiology

van Walsem et al. (2022) "Quality of life, utilization, and costs in HD (Norway)." PMID: 36517848
Domaradzki (2015) "Impact of HD on Family Carers." PMID: 26688844

Emerging Science

Maimon (2026) "Huntington's disease is the best investment in neuroscience today." PMID: 41690900
Gavgani & García-Domínguez (2025) "Breakthroughs in AAV-Mediated Gene Therapy for HD." PMID: 41090742
Gulzar et al. (2026) "Therapeutic strategies for HD: current approaches and future." PMID: 40874597
Louessard et al. (2024) "HTT roles in striatal development and neuronal functions." PMID: 38427495

Report compiled: April 2026 | Based on 69+ literature sources, Wikidata SPARQL queries, and domain knowledge 13 confirmed findings recorded in knowledge graph across 5 iterations

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Definitions

Inheritance

Subtypes

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Clinical Trials

Source YAML

References & Deep Research

Deep Research

Huntington Disease: Comprehensive Disease Characteristics Report

Executive Summary

1. Genetic Basis

1.1 The HTT Gene and CAG Repeat Expansion

1.2 CAG Repeat Length Categories

1.3 CAG Length and Age of Onset

1.4 Anticipation

2. Disease Identifiers

3. Epidemiology

3.1 Prevalence

3.2 Incidence

3.3 Population Variation

4. Huntingtin Protein Biology

4.1 Protein Structure

4.2 Normal Functions of Wild-Type Huntingtin

4.3 Key Post-Translational Modifications

4.4 Signaling Pathways Involving HTT

5. Molecular Pathogenesis

5.1 Mutant Huntingtin Protein (mHTT) Toxicity

5.2 Key Pathogenic Mechanisms

5.3 Selective Neuronal Vulnerability

6. Neuropathology

6.1 Vonsattel Grading System

6.2 Brain Regions Affected (in order of severity)

7. Clinical Features

7.1 The Clinical Triad

Motor Symptoms

Cognitive Symptoms

Psychiatric Symptoms (often precede motor onset)

7.2 Other Clinical Features

7.3 Disease Stages (Shoulson-Fahn Total Functional Capacity)

7.4 Juvenile Huntington Disease (JHD)

8. The Premanifest Phase: A Window for Intervention

8.1 Timeline of Premanifest Changes

8.2 Key Observational Studies

8.3 Therapeutic Implications

9. Differential Diagnosis

9.1 Genetic HD Phenocopies (HTT-Negative)

9.2 Acquired Causes of Chorea

9.3 Diagnostic Algorithm

10. Diagnosis

10.1 Clinical Diagnosis

10.2 Genetic Testing

10.3 Neuroimaging

10.4 Fluid Biomarkers

11. Current Treatment

11.1 Approved Symptomatic Therapies

11.2 Off-Label and Supportive Treatments

11.3 No Disease-Modifying Therapy Is Currently Approved

12. Therapeutic Pipeline and Emerging Strategies

12.1 HTT-Lowering Approaches

12.2 Somatic Expansion Inhibitors (Novel Paradigm)

12.3 Other Approaches

13. Animal Models

14. Key Emerging Concepts

14.1 HD as a Developmental Disorder

14.2 Somatic Instability as the Central Disease Driver

14.3 Peripheral Pathology

14.4 Biomarker-Driven Clinical Trials

15. Genetic Counseling and Predictive Testing

15.1 Predictive Testing Framework